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SUMMARY  
Acinetobacter baumannii has emerged as one of the most troublesome nosocomial pathogens 
globally. This organism causes infections that are often extremely difficult to treat because of the 
widespread resistance to the major antibiotic groups. Colonization or infection with multidrug-
resistant A. baumannii is associated with the following risk factors: prolonged hospital stay, 
admission to an intensive care unit (ICU), mechanical ventilation, and exposure to broad spectrum 
antibiotics, recent surgery, invasive procedures, and severe underlying disease. 
 
A. baumannii has been isolated as part of the skin flora, mostly in moist regions such as axillae, 
groin and toe webs. It has also been isolated from the oral cavity and respiratory tract of healthy 
adults. Debilitated hospitalized patients have a high rate of colonization, especially during 
nosocomial Acinetobacter outbreaks. This organism is an opportunistic pathogen as it contains 
few virulence factors. Clinical manifestations of A. baumannii include nosocomial pneumonia, 
nosocomial bloodstream infections, traumatic battlefield and other wound infections, urinary tract 
infections, and post-neurological surgery meningitis. Fulminant community-acquired pneumonia 
has recently been reported, indicating that this organism can be highly pathogenic. 
 
The number of multidrug-resistant A. baumannii strains has been increasing worldwide in the past 
few years. Therefore the selection of empirical antibiotic treatment is very challenging. Antibiotic 
combinations are used mostly as empirical therapy in critically ill patients. One rationale for the 
use of combination therapy is to achieve synergy between agents. 
 
The checkerboard and time-kill methods are two traditional methods that have been used for 
synergy testing. These methods are labor intensive, cumbersome, costly, and time consuming. 
The E-test overlay method is a modification of the E-test method to determine synergy between 
the different antibiotics. This method is easy to perform, flexible and time efficient. 
 
The aim of this study was to assess the in vitro activity of different combinations of colistin, 
rifampicin, imipenem, and tobramycin against selected clinical strains of A. baumannii using the 
checkerboard and the E-test synergy methods. The MICs obtained with the E-test and broth 
microdilution method were compared. The results of the disk diffusion for imipenem and 
tobramycin as tested in the routine microbiology laboratory were presented for comparison. 
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Overall good reproducibility was obtained with all three methods of sensitivity testing. The 
agreement of MICs between the broth dilution and E-test methods was good with not more than 
two dilution differences in MIC values for all isolates, except one in which the rifampicin E-test MIC 
differed with three dilutions from the MIC obtained with the microdilution method. However, the 
categorical agreement between the methods for rifampicin was poor. Although MICs did not differ 
with more than two dilutions in most cases, many major errors occurred because the MICs 
clustered around the breakpoints. 
 
 
The combinations of colistin + rifampicin, colistin + imipenem, colistin + tobramycin, rifampicin + 
tobramycin, and imipenem + tobramycin all showed indifferent or additive results by the E-test 
method. No results indicating synergy were obtained for all the above-mentioned combinations. 
There was one result indicating antagonistic effect for the combination of colistin + tobramycin. 
 
The results of the checkerboard method showed results indicating synergy in four of the six 
isolates for which the combination of colistin and rifampicin was tested. The other two isolates 
showed indifferent/additive results. All the other combinations showed indifferent/additive results 
for all isolates except isolate 30 (col + tob) and isolate 25 (rif + tob) which showed synergism. No 
antagonistic results were observed by the checkerboard method. 
 
When the results obtained with the E-test and checkerboard methods were compared, it was 
noted that for most antibiotic combinations an indifferent/additive result was obtained. However, 
for the colistin + rifampicin combination, the checkerboard method showed synergism for 4 of 6 
isolates, whereas the E-test method showed indifference and an additive result in one. For the 
rifampicin + tobramycin, and colistin + tobramycin combinations, synergism was also shown with 
the checkerboard method in one isolate for each combination. The E-test method however 
showed an indifferent and additive result respectively. 
. 
The E-test method was found to be a rapid, reproducible, easy-to-perform, and flexible method to 
determine synergistic antibiotic activity. This study was however limited by low numbers of 
isolates. This might explain why no synergistic results were obtained with the E-test method and 
few synergistic results with the checkerboard method. Genotypic analysis using pulse-field gel 
electrophoresis (PFGE) may be considered in future studies to determine relatedness of the 
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isolates which will facilitate the selection of different strains for synergy testing. Furthermore, 
clinical studies are needed to establish whether in vitro synergy testing is useful in the clinical 
setting and whether the results of synergy testing will have any bearing on the clinical outcome of 
patients infected with multidrug resistant A. baumannii.  
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OPSOMMING  
Acinetobacter baumannii het wêreldwyd as een van die mees problematiese nosokomiale 
patogene verskyn. Hierdie organisme veroorsaak infeksies wat dikwels baie moeilik is om te 
behandel weens wydverspreide weerstandigheid teen major antibiotikagroepe. Kolonisasie of 
infeksie met multi-weerstandige A. baumannii word geassosieer met die volgende riskofaktore: 
verlengde hospitaalverblyf, toelating tot ‘n intensiewe sorgeenheid (ICU), meganiese ventilasie, 
blootstelling aan breëspektrum antibiotika, onlangse chirurgie, indringende prosedures en  
ernstige onderliggende siekte. 
 
A. baumannii kan deel vorm van die normale velflora, veral in die axillae, inguinale area en tussen 
die tone. Dit is ook al vanuit die mondholte en die respiratoriese traktus van gesonde volwassenes 
geïsoleer. Verswakte gehospitaliseerde pasiënte word veral gekoloniseer  gedurende nosokomiale 
Acinetobacter uitbrake. Hierdie organisme is ‘n opportunistiese patogeen en bevat min virulensie 
faktore. Kliniese manifestasies van A. baumannii sluit nosokomiale pneumonie, nosokomiale 
bloedstroom infeksies, troumatiese slagveld- en ander wondinfeksies, urienweginfeksies en 
meningitis wat volg op neurologiese chirurgie in. Fulminerende gemeenskapsverworwe 
pneumonie is onlangs beskryf en dui aan dat hierdie organisme hoogs patogenies kan wees. 
 
Die aantal multi-weerstandige A. baumannii stamme het wêreldwyd toegeneem oor die laaste 
paar jare. Daarom is die seleksie van empiriese antibiotiese behandeling ‘n uitdaging. Antibiotika 
kombinasies word meestal as empiriese behandeling in ernstige siek pasiënte gebruik. Die 
beginsel hiervan is om sinergistiese werking tussen agente te verkry.  
 
Die “checkerboard” en “time-kill” metodes is twee tradisionele metodes van sinergisme toetsing. 
Hierdie metodes is werksintensief, duur en tydrowend. Die E-toets sinergisme metode is gebaseer 
op die E-toets metode. Hierdie metode is maklik, buigbaar en tydseffektief. 
 
Die doel van hierdie studie was om die in vitro aktiwiteit tussen verskillende antibiotika 
kombinasies van colistin, rifampisien, imipenem, en tobramisien teen geselekteerde kliniese A. 
baumannii isolate te toets met die “checkerboard” en E-toets sinergisme toetsing metodes. Die 
minimum inhibitoriese konsentrasies (MIKs) verkry met die E-toets en “broth microdilution” metode 
is ook vergelyk. Die resultate van die skyfie diffusie metode (die metode wat in die roetiene 
 ix
mikrobiologie laboratorium gebruik word) vir imipenem en tobramisien word ook verskaf vir 
vergelyking van die resultate van verskillende sensitiwiteitsmetodes. 
 
In oorsig is goeie herhaalbaarheid van resultate verkry met al drie metodes van 
sensitiwiteitstoetsing. Die ooreenstemming van MIKs tussen die “broth dilution” en E-toets 
metodes was goed en  resultate het met nie meer as twee verdunnings in MIK waardes verskil nie. 
Daar is een uitsondering waar die rifampisien E-toets MIK waarde met drie verdunnings van die 
MIK waarde verkry met die “microdilution” metode verskil. Die ooreenstemming tussen die 
sensitiwiteitskategorie resultate tussen die twee metodes was egter swak vir rifampisien. Alhoewel 
die MIKs in die meeste gevalle met nie meer as twee verdunnings in waarde verskil het nie, was 
daar baie major foute aangetoon omdat die MIKs rondom die breekpunte geval het. 
 
 
Die kombinasies van colistin + rifampisien, colistin + imipenem, colistin + tobramisien, rifampisien 
+ tobramisien, en imipenem + tobramisien het oorwegend slegs matige interaksie met die E-toets 
metode getoon. Geen sinergisme is verkry met enige van die antibiotika kombinasies met hierdie 
metode nie. Daar was egter een resultaat wat antagonisme getoon het vir die kombinasie van 
colistin + tobramycin. 
 
Die resultate van die “checkerboard” metode het sinergisme getoon in vier van die ses isolate wat 
vir die kombinasie van colistin en rifampisien getoets was. Die ander twee isolate het slegs matige 
interaksie getoon.  Al die ander kombinasies het ook slegs matige interaksie getoon, behalwe in 
isolaat 30 (col + tob) en isolaat 25 (rif + tob) waar die spesifieke kombinasies sinergisme getoon 
het. Geen antagonisme is waargeneem met die “checkerboard” metode nie. 
 
Met vergelyking van die E-toets en “checkerboard” metodes, is dit opmerklik dat vir die meeste 
van die antibiotika kombinasies slegs matige interaksie verkry is. Vir die colistin + rifampisien 
kombinasie toon die “checkerboard” metode egter sinergisme vir 4 uit 6 isolate, terwyl die E-toets 
metode slegs matige interaksie toon. Vir rifampisien + tobramisien, en colistin + tobramisien 
kombinasies is sinergisme getoon met die “checkerboard” metode in een isolaat vir elke 
kombinasie. Die E-toets metode het slegs matige interaksie getoon. 
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Die E-toets sinergisme metode was vinnig, herhaalbaar en maklik om uit te voer. Hierdie studie 
word egter beperk deur lae getalle van isolate. Dit mag verklaar waarom geen sinergistiese 
resultate met die E-toets metode verkry is nie en die min sinergistiese resultate met die 
“checkerboard” metode. Genotipiese analiese met “pulse-field gel electrophoresis” mag in 
aanmerking geneem word in toekomstige studies om die verwantskap tussen isolate te bepaal wat 
die seleksie van verskillende stamme vir sinergisme toetsing sal vergemaklik. Verder, kliniese 
studies is nodig om te bepaal of in vitro sinergisme toetsing van waarde is en of die resultate van 
sinergisme toetsing ‘n rol speel in die kliniese uitkoms van pasënte geïnfekteer met multi-
weerstandige A. baumannii.  
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IN VITRO ANTIMICROBIAL SYNERGY TESTING OF  
ACINETOBACTER BAUMANNII 
I. Introduction 
 
Acinetobacter baumannii has emerged as one of the most troublesome nosocomial pathogens globally 
(Peleg A.Y., 2008). It has a remarkable ability to up-regulate or acquire resistance determinants. Infections 
due to this organism are often extremely difficult to treat because of the widespread resistance to the major 
antibiotic groups (Bergogne-Berezin E .1996). The emergence of multidrug resistant strains of A. 
baumannii has resulted in carbapenems becoming the mainstay treatment for Acinetobacter infections 
(Towner, 2009). Recently, though, there are increasing reports of carbapenem resistance accumulating 
worldwide. Some of these isolates are resistant to all conventional antibiotics. This resistance causes 
challenges in antibiotic selection for empirical therapy. Empirical therapy should thus rely on institutional-
level data concerning the phenotypes and genotypes of A.  baumannii strains endemic in a particular 
hospital (Towner, 2009).  
 
There is a lack of large controlled clinical trials focusing on the treatment of A. baumannii infections 
(Maragakis L.L., 2008; Towner, 2009). This makes it difficult to evaluate the role of antimicrobial synergy of 
combination therapy (Maragakis L.L., 2008). Information about the best therapeutic approaches is based 
on in-vitro susceptibility data, small case series and retrospective analysis of observational studies 
(Towner, 2009).  
 
In vitro testing has been used by researchers for some time now, for accurate prediction of clinically 
relevant antimicrobial synergy (White R.L., 1996). The most widely used methods for in vitro synergy are 
the checkerboard and the time-kill curve methods. The epsilometer (E-test) strip has also been used in vitro 
for performing synergy testing (White R.L., 1996). These three methods have been compared in previous 
studies (White R.L., 1996; Bonapace C.R., 2000). Agreement of qualitative interpretation was 
demonstrated among these methods, even though they use different endpoints (Bonapace C.R., 2000). 
There has however been conflicting results between studies testing the same antimicrobial combinations 
against Acinetobacter isolates (Maragakis L.L., 2008). 
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II. Literature Review: Acinetobacter baumannii 
 
1. Current taxonomy 
 
The genus Acinetobacter is characterized by a long history of taxonomic changes. These organisms have 
been moved from the family Neisseriaceae to the family Moraxellaceae (Fournier P.E., 2006). There are at 
least 25 different Acinetobacter strains which fulfill the criteria to be considered distinct species. These 
have been identified by DNA-DNA hybridization studies (Fournier P.E., 2006). These studies have also 
been used to delineate 15 genomic species (gen. sp.) which do not yet have valid names (Dijkshoorn L, 
2007). These genomic species are commonly labeled by the initials of their authors e.g. Tjernberg and 
Using (TU) or Bouvet and Jeanjean (BJ) (Dijkshoorn L, 2007). 
 
Acinetobacters are Gram negative coccobacilli, that are strictly aerobic and non-motile (occasionally 
showing twitching motility) ((Bergogne-Berezin E . 1996). The organisms exist as bacilli during rapid growth 
and coccobacilli in the stationary phase and have a tendency of retaining crystal violet, thus may be 
incorrectly identified as Gram-positive cocci.  
 
It is difficult to differentiate Acinetobacter isolates according to their phenotypic characteristics (Fournier 
P.E., 2006; Peleg A.Y., 2008). This has led to the use of the term A. calcoaceticus – A. baumannii complex 
(Fournier P.E., 2006). The complex includes genomic species 1 (A. calcoaceticus), 2 (A. baumannii), gen. 
sp. 3, and 13TU, which show an extremely close relationship (Bergogne-Berezin E . 1996). A. baumannii 
seems to be the species of greatest clinical importance. Repeated isolation of other species from the A. 
calcoaceticus – A. baumannii complex might be significant, especially if clinical symptoms are also present 
(Bergogne-Berezin E . 1996),(Peleg A.Y., 2008). A. calcoaceticus is an environmental species that has 
been recovered from soil and water but has not been implicated in serious clinical disease ((Peleg A.Y., 
2008). Figure  1 below shows the delineation of Acinetobacter genomic species.  
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Figure 1: Delineation of Acinetobacter genomic species.  
Reproduced from: (Peleg A.Y., 2008) 
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2. Species of clinical importance 
 
Acinetobacter spp. may form part of the human skin flora. Not all species of the genus Acinetobacter have 
their natural habitat in the environment. The skin carriage rate of all Acinetobacter species can be as high 
as 75% among hospitalized patients, and up to 25% among healthy individuals (Seifert H., 1997). A. 
baumannii and gen. sp. 13TU, on the other hand, were found only rarely on human skin in the study by 
Seifert et al., which looked at the distribution of Acinetobacter spp. on human skin of 40 cardiology patients 
and 40 healthy controls  (Seifert H., 1997).  
 
A. baumannii is the main genomic species associated with nosocomial outbreaks (Bergogne-Berezin E . 
1996). Many reports of infection due to A. baumannii however do not include the necessary tests for 
specific identification to species level, but give a presumptive identification (Bergogne-Berezin E., 1996). 
There is a need for further investigations to define the clinical significance of Acinetobacter species other 
than A. baumannii, because these isolates are often considered as contaminants derived from the 
environment (Bergogne-Berezin E., 1996). However, genomic species 3 and 13TU have been implicated in 
nosocomial infections and A. johnsonnii has been reported to cause catheter related bacteremia. The main 
sites of infections due to A. baumannii are the lower respiratory tract and the urinary tract (Bergogne-
Berezin E., 1996). 
 
3. Laboratory identification 
 
Precise species identification of Acinetobacter is not necessary in the routine clinical laboratory. The term 
A. baumannii group is sufficient for laboratory diagnosis. Exact strain identification may be required for 
epidemiologic purposes to identify strain relatedness. Various methods are available for molecular typing of 
strains for epidemiological purposes. There are also molecular methods which have been validated for the 
identification of Acinetobacter. Examples of these molecular methods are: amplified 16S rRNA gene 
restriction analysis, high resolution fingerprint analysis by amplified fragment length polymorphism, 
ribotyping, tRNA spacer fingerprinting, restriction analysis of the 16S – 23S rRNA intergenic spacer region 
and sequencing of the rpoB gene. All the above mentioned methods are too labor intensive to be used 
routinely in the clinical microbiology laboratory (Peleg A.Y., 2008).  
Manual and semi-automated commercial identification systems are currently being used for species 
identification in the clinical microbiology laboratory. Examples are the API 20NE, Vitek 2, Phoenix, and 
Microscan WalkAway systems. The problem with these systems is their limited database content and the 
fact that they use identification substrates which have not been tailored specifically for Acinetobacter 
identification (Peleg A.Y., 2008). All the currently available commercial methods cannot differentiate 
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clinically relevant members of the A. calcoaceticus – A. baumannii complex. A. baumannii, Acinetobacter 
genomic species 3, and Acinetobacter genomic species 13TU are uniformly identified as A. baumannii. It is 
thus advisable to use the term A. baumannii group instead of A.  calcoaceticus – A. baumannii complex 
when referring to these species. The distinction between A. baumannii group and Acinetobacter spp. 
outside the A. baumannii group has important infection control implications. Acinetobacter spp. outside the 
A. baumannii group rarely causes nosocomial outbreaks and therefore do not necessitate infection control 
measures (Peleg A.Y., 2008). 
 
Acinetobacters are non-fastidious organisms that grow well on common laboratory media consisting of 
nutrient agar and tryptic soy agar (Bergogne-Berezin E . 1996). Clinical isolates, mostly A. baumannii, gen 
spp. 3, and 13TU, grow at 35 - 37 ˚C or higher, whilst some other genomic species grow only at lower 
temperatures. Most Acinetobacter strains can grow in a simple mineral medium containing a single carbon 
and energy source (Bergogne-Berezin E . 1996). Some Acinetobacter species outside the A. calcoaceticus 
– A. baumannii complex may not grow on McConkey agar. Some species may show hemolysis on sheep 
blood agar (e.g. A. haemolyticus). Members of the A. calcoaceticus – A. baumannii complex are never 
hemolytic on sheep blood agar. However, there is no single metabolic test which enables unambiguous 
identification of Acinetobacter species from other similar bacteria (Peleg A.Y., 2008). 
 
DNA – DNA relatedness is used to classify Acinetobacter isolates into genomic species. The different DNA 
hybridization methods which have been employed are the nitrocellulose filter method, the S1 endonuclease 
methods, the hydroxyapatite method and a quantitative bacterial dot filter method. The latter method is the 
simplest, with the others being more labor intensive and not suitable for routine microbiological use 
(Bergogne-Berezin E . 1996). The DNA – DNA hybridization method is the gold-standard among the few 
validated methods for identification of Acinetobacter species (Peleg A.Y., 2008). 
 
4. Epidemiology 
 
Acinetobacter may form part of the skin flora, mostly in moist regions such as the axillae, groin and toe 
webs. They have also been isolated from the oral cavity and respiratory tract of healthy adults. The carriage 
rate in non-hospitalized patients, apart from on the skin, is generally low (Bergogne-Berezin E . 1996). 
Debilitated hospitalized patients have a high rate of colonization, especially during nosocomial 
Acinetobacter outbreaks. The predominant site of colonization in these patients is the skin, but respiratory 
tract or digestive systems may also be colonized. The differences between carriage rates between 
outpatients and hospitalized patients suggest that infecting or colonizing organisms in hospital patients may 
be acquired from cross-transmission or from hospital environmental sources and is usually not derived from 
endogenous patient sources (Bergogne-Berezin E . 1996). Colonization or infection with multidrug – 
resistant Acinetobacter is associated with the following risk factors: prolonged hospital stay, admission to 
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an intensive care unit (ICU), mechanical ventilation, and exposure to broad spectrum antibiotics, recent 
surgery, invasive procedures, and severity of the underlying disease (Maragakis L.L., 2008).  
To investigate the environmental habitat of Acinetobacter, the distribution and frequency of Acinetobacter 
species in a variety of purchased and harvested fresh fruit and vegetables have been studied. 
Acinetobacter was isolated in 17% (30 of 177) samples of the produce. A. baumannii complex formed 56% 
of all isolates from cucumbers, peppers, mushrooms, lettuces, potatoes, corns, cauliflowers, radishes, 
mushrooms, melons, cabbages, apples, and beans. According to this study hospital food could be a natural 
habitat and a source for A. baumannii acquisition and subsequent colonization of the digestive tract of 
hospitalized patients (Berlau J., 1999).  
 
A. baumannii has also been isolated from wounds of injured American and British soldiers from Afghanistan 
and Iraq. These strains were multidrug-resistant and mostly were part of polymicrobial infections (Paolino 
K., 2007 ). The sources for these infections were unknown, but it was suggested that prolonged 
environmental contamination of military field hospitals played a role as Acinetobacter species can survive in 
both moist and dry environments (Giamarellou H., 2008). Interestingly, in a study done in France, A. 
baumannii strains were isolated from body lice of homeless people. The researchers demonstrated that 
body lice were vectors of A. baumannii. This indicated that A. baumannii was epidemic in human body lice. 
A. baumannii association with body lice is likely due to undiagnosed transient A. baumannii bacteremia in 
people infested with body lice (La Scola B., 2004). 
 
A review article by Villegas and Hartstein (Villegas M.V., 2003) provided examples of locations in the 
hospital environment where Acinetobacter has been isolated. Common sources for this organism included 
ventilator tubing, suction catheters, humidifiers, containers of distilled water, urine collection jugs, 
intravenous nutrition, multi-dose vials of medication, potable water, moist bedding articles, and 
inadequately sterilized reusable arterial transducers (Villegas M.V., 2003). In an outbreak of Acinetobacter 
infection in burns patients, wet mattresses served as environmental reservoirs of Acinetobacter (Sherertz 
R.J., 1985). Contaminated bedding materials may play an important role in the nosocomial spread of these 
organisms (Bergogne-Berezin E . 1996). Medical equipment can get contaminated through contact with 
both the patients and staff during handling. Therefore hospital staff may be responsible for contaminating 
equipment if they do not adhere to infection control measures. In respiratory ICUs, respiratory equipment 
can be a source of persistent outbreaks due to inadequate decontamination after use (Bergogne-Berezin 
E,. 1996). 
 
Acinetobacter has an ability to persist in the hospital environment, thus are able to cause extended 
outbreaks (Bergogne-Berezin E., 1996). In one outbreak, the presence of airborne Acinetobacter species 
was demonstrated by settle plates (Allen K.D., 1987). The source of these organisms was probably the skin 
of infected or colonized patients, and/or contaminated fomites, e.g. bed linen and curtains. Airborne 
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Acinetobacter produces extensive environmental contamination, and was found to persist in the 
environment for up to 13 days after patient discharge (Allen K.D., 1987). Thus, there is a possible 
interchange between patients, hospital staff and inanimate items, allowing the survival of nosocomially 
important pathogens (Getchell-White S.I., 1989).  
Acinetobacter differ from other gram negative bacteria in that they spread easily in the environment 
surrounding infected or colonized patients. In an in vitro study it was shown that the ability of A. baumannii 
strains to survive under dry conditions varied greatly (Wendt C., 1997). This ability correlated well with the 
source of the strain. Those strains which were isolated from dry sources tended to survive longer than the 
ones derived from wet sources (Wendt C., 1997).  
 
5. Pathogenesis of Acinetobacter baumannii infections 
 
Acinetobacters cause opportunistic infections because of limited number of virulence factors and are thus 
considered as low grade pathogens (Bergogne-Berezin E., 1996). Recently, there have been a number of 
case-reports of fulminating community – acquired pneumonia which indicated that these organisms may 
sometimes be highly pathogenic and cause invasive disease (Joly-Guillou, 2005). There are certain 
characteristics of this organism that can enhance its virulence. These include the presence of a capsular 
polysaccharide which makes the organism to be hydrophilic, the ability to adhere to human epithelial cells 
in the presence of fimbriae and/or capsular polysaccharides, the production of lipases which can damage 
tissue lipids and the presence of cell wall lipopolysaccharide and lipid A which are potentially toxic 
(Bergogne-Berezin E., 1996). The lipopolysaccharide causes resistance to complement in human serum 
and acts synergistically with capsular exopolysaccharide (Joly-Guillou, 2005). Little else is known about 
Acinetobacter’s lipopolysaccharide endotoxigenic potential in humans. The capsule is a major virulence 
factor and is presumed to protect bacteria from host defenses (Joly-Guillou, 2005). Quorum – sensing as a 
widespread regulatory mechanism in gram negative bacteria has been found in clinical isolates of 
Acinetobacter. It might be a central mechanism for auto-induction of multiple virulence factors in 
Acinetobacter (Joly-Guillou, 2005).  
 
Mixed infections involving Acinetobacter and other bacteria are more virulent than infections with 
Acinetobacter species alone (Bergogne-Berezin E., 1996). Acinetobacter species have the ability to obtain 
the necessary iron for growth in the human body. This is also an important virulence determinant 
(Bergogne-Berezin E . 1996).  
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6. Clinical manifestations of Acinetobacter baumannii infections 
a. Nosocomial pneumonia  
 
There is a persistent seasonal variation in the rate of Acinetobacter infection. This variation tends to 
increase in late summer for all major infection sites (McDonald L.C., 1999). Presently the most important 
role of Acinetobacter is as a cause of nosocomial pneumonia, mostly following the use of mechanical 
ventilation in ICU patients (Joly-Guillou, 2005; Bergogne-Berezin E., 1996). The role played by 
Acinetobacter species in ventilator associated pneumonia (VAP) appears to be increasing (Bergogne-
Berezin E., 1996). An increase from 0.64% to 6.4% in the incidence of nosocomial pneumonia due to 
Acinetobacter between 1976–1990 has been reported in a surveillance program of the Nosocomial 
Infections Surveillance (NNIS) System in the USA which involved adult and pediatric patients (McDonald 
L.C., 1999).  
 
Today, there are many major advances in the management of ventilated patients and there is routine use of 
effective procedures to disinfect respiratory equipment. These have not affected the increased incidence of 
VAP due to Acinetobacter (Bergogne-Berezin E., 1996). Although it is often very difficult to distinguish 
upper respiratory tract colonization from true pneumonia, ventilator-associated pneumonia due to A. 
baumannii does occur (Peleg A.Y., 2008). The acquisition of A. baumannii infection in the ICU is associated 
with a high APACHE II score, cardiovascular failure, respiratory failure, previous infection, previous 
antibiotic therapy, use of mechanical ventilation and the presence of a central venous or urinary catheter 
(Lortholary O., 1995).  
 
The prognosis associated with nosocomial pneumonia is considerably worse than that due to other Gram-
negative or Gram-positive bacteria, except for Pseudomonas aeruginosa (Bergogne-Berezin E., 1996)). 
Acinetobacter nosocomial pneumonia is a severe disease in ventilated patients. It is not easy to ascertain 
whether such critically ill patients would have survived if nosocomial pneumonia had not occurred 
(Bergogne-Berezin E., 1996). Fagon et al. looked at the extent to which nosocomial pneumonia increased 
mortality and hospital stay in ventilated patients by performing a matched retrospective cohort study in a 
Paris hospital (Fagon J., 1993). The authors diagnosed pneumonia by use of quantitative culture of 
samples from protected specimen brush and observation of intracellular organisms from bronchoalveolar 
lavage. They were able to match cases and controls for confounders like severity of underlying illness, age 
and reason for ventilation. VAP caused by Pseudomonas or Acinetobacter species was associated with 
considerable mortality in excess of that due to the underlying disease alone (Fagon J., 1993). The mortality 
attributed to Acinetobacter or Pseudomonas infection exceeded 40%, with a relative risk of death of 2.5. 
There was also a significantly prolonged hospital stay in the ICU by more than 10 days in patients 
diagnosed with pneumonia (Fagon J., 1993). 
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b. Community –acquired pneumonia 
 
Most studies of community-acquired pneumonia due to A. baumannii (CAP-AB) originated from China, 
Taiwan, and Australia (Falagas M. E., 2007). The disease mostly occurs in patients with the following co-
morbidities: chronic obstructive pulmonary disease (COPD), renal disease, diabetes mellitus, alcoholism, 
and heavy smoking. Community – acquired Acinetobacter infections are caused by isolates that are more 
susceptible than hospital-acquired strains (Falagas M. E., 2007). Clinically, patients with CAP-AB present 
with acute onset of dyspnea, cough and fever that tend to rapidly progress to respiratory failure and shock 
(Leung W., 2006). When compared to hospital-acquired pneumonia due to A. baumannii (HAP-AB), CAP-
AB patients are likely to be smokers and have COPD. The clinical presentation tends to be more 
fulminating in CAP-AB and associated with bacteremia, acute respiratory distress syndrome (ARDS), 
disseminated intravascular coagulation (DIC) and early death. The mortality of patients with community 
acquired Acinetobacter pneumonia and /or bacteremia is considerable (Falagas M. E., 2007; Leung W., 
2006) and can be as high as 64% (Anstey N. M., 1992). This high mortality rate can be explained by the 
large number of risk factors affecting patients with CAP-AB, the relatively higher average age, or 
inappropriate empiric treatment (Leung W., 2006).  
 
c. Nosocomial bloodstream infections 
 
The major and frequent manifestation of infection caused by A. baumannii is bacteremia, followed by 
respiratory tract and surgical wound infections (Cisneros J.M., 2002). During a nationwide, concurrent 
surveillance study done in the USA (1995 – 2002), to examine trends in the epidemiology and microbiology 
of nosocomial bloodstream infections, A. baumannii was the 10th most common etiologic agent 
(Wisplinghoff H., 2004). This organism was responsible for 1.3% of all monobacterial nosocomial 
bloodstream infections (0.6 bloodstream infection per 10 000 admissions) (Wisplinghoff H, 2004 ). The 
mean interval between admission and infection was 26 days for Acinetobacter species and most of the 
infections were in patients admitted in intensive care unit (Wisplinghoff H., 2004 ). A. baumannii 
bloodstream infection had a crude mortality rate of 34% - 43.4% in ICU, and 16.3% in the general wards. 
Pseudomonas aeruginosa (crude mortality - 38.7%) and Candida species (crude mortality - 39.2%) were 
the only organisms with crude mortality rates above A. baumannii (crude mortality 34-43.4%) in ICU 
patients (Wisplinghoff H., 2004 ). 
   
In a single center study in Seville, Spain, there were 1.8 episodes of bacteremia due to A. baumannii per 
1000 adults admitted to the hospital (Cisneros J.M., 1996). Of these patients, 25% had serious, debilitating 
chronic diseases (Cisneros J.M., 1996). Other risk factors for bacteremia included invasive procedures 
such as intravascular catheterization, urinary tract catheterization, mechanical ventilation, and prior 
surgery. Septic shock due to A. baumannii bacteremia can be as high as 25 – 30% (Cisneros J.M., 1996).   
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d. Traumatic battlefield and other wound infections 
 
Injured and ischemic tissue in trauma patients facilitates colonization with A. baumannii (Oncul O., 2002). 
A. baumannii has been isolated from wounds of war casualties from Iraq and Afghanistan. In one study A. 
calcoaceticus-baumannii complex formed 32.5% of initial wound cultures. It did not appear to directly 
contribute to any substantial morbidity (viz. persistent nonunion or amputation), thus signifying that this 
organism is of low pathogenicity in wound infections (Johnson E. N., 2007). Gunshot wounds and external 
fixation tend to be associated with increased risk of Acinetobacter infection (Petersen K, 2007).   
 
Most Acinetobacter infections in war casualties are caused by highly antibiotic-resistant strains. These 
infections occur in critically ill patients with severe traumatic injuries. These organisms are acquired through 
nosocomial transmission in field hospitals (Scott P., 2007). Murray et al. (Murray C.K., 2006) found that 
Acinetobacter species were not isolated from wounds immediately after or soon after injury from casualties 
who were treated at a US Military field hospital in Iraq. In a study by Petersen et al (Petersen K, 2007), 
which looked at trauma related infections in Iraqi war casualties, Acinetobacter followed by Pseudomonas 
species, and Escherichia coli were the most common wound isolates. Environmental contamination and 
transmission of organisms within healthcare facilities seem to play a significant role in acquiring 
Acinetobacter wound infection (Scott P., 2007).  
 
The circumstances of combat are extremely challenging (Zapor M.J., 2005). Infection control measures 
such as cohorting, isolation and even proper hand washing techniques are very difficult, especially in mass 
casualty situations. This leads to ongoing colonization, and at the end, to wound infection (Zapor M.J., 
2005). Complicated soft tissue and bone infection may follow. An increase in the rate of osteomyelitis 
caused by Acinetobacter was described in soldiers stationed in southwest Asia (Zapor M.J., 2005). 
Traumatic wounds related to natural disasters may also involve Acinetobacter. A. baumannii has been 
isolated from traumatic wounds sustained during an earthquake in Marmara, northwest of Turkey (Oncul 
O., 2002). 
 
e. Urinary Tract Infections (UTI) 
 
In many cases A. baumannii isolated from respiratory secretions and urinary tract specimens collected from 
hospitalized patients signify colonization rather than infection (Fournier P.E., 2006). Most infections due to 
this organism are from organ systems with a high fluid content, e.g. respiratory tract, peritoneal fluid and 
the urinary tract. These infections are associated with indwelling devices (Fournier P.E., 2006). A. 
baumannii is not usually implicated in uncomplicated UTI in healthy outpatients (Peleg A.Y., 2008). In a 
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study looking at trends in Gram-negative pathogen distribution in ICUs (1986 – 2003) (Gaynes R., 2005), 
Acinetobacter isolates comprised 1.6% of pathogens associated with UTIs in the ICU. Investigators in 
Spanish hospitals looked at 206 patients colonized or infected with A. baumannii. UTIs constituted 23%, 
second only to respiratory tract infections (39%) (Rodriguez-Baño J., 2004). A. baumannii UTIs tend to 
show seasonal variability (Fournier P.E., 2006). The reason for the seasonal variability is unknown, but was 
observed also in a study done by McDonald (McDonald L.C., 1999). 
 
f. Meningitis 
 
There is a steady increase in cases of nosocomial, post-neurological surgery A. baumannii meningitis 
(Peleg A.Y., 2008); (Kim M., 2009 ). Community-acquired meningitis due to A. baumannii on the other hand 
is very rare (Kim M., 2009). Patients with post-neurological surgery central nervous system (CNS) infection 
tend to be young, acquire the infection in hospital, commonly have no severe underlying diseases, and 
have a slow clinical course (Lu C., 1999). Mortality due to Acinetobacter meningitis has been cited to be 
23% (Siegman-Igra Y., 1993).  In this case series, patients were predominantly adult males and the most 
significant risk factor was the presence of a continuous connection between the ventricles and the external 
environment. The median time to develop Acinetobacter meningitis following a neurosurgical procedure 
was 12 days (range 1 – 40 days) (Siegman-Igra Y., 1993). These types of infections can be prevented by 
maintaining a closed drainage system together with timely removal of the ventricular catheters. 
Furthermore, the selective pressure of the antibiotics used in the neurosurgical ICU favors the growth of 
multi-drug resistant Acinetobacter.  
 
Pseudomeningitis may occur, where the CSF culture is positive for Acinetobacter in the absence of clinical 
and laboratory features of meningitis (Kim M., 2009). Contamination of the CSF may occur during 
specimen collection as this organism is increasingly prevalent in the hospital environment and may colonize 
the skin. The specimen may also become contaminated due to contaminated specimen tubes and in the 
laboratory, contaminated pipettes and media. In a study by Chen (Chen H., 2005), lumbar puncture derived 
Acinetobacter isolates were more clinically insignificant than those obtained from previously placed 
ventricular drains. Differentiating between clinically significant and insignificant isolates enables clinicians to 
avoid unnecessary antibiotic treatments and helps with timely and accurate treatment of infected patients 
(Chen H., 2005). Most significant cases are associated with neurosurgical procedures (Chen H., 2005), 
(Kim M., 2009 ). With regard to clinical signs and symptoms in Acinetobacter meningitis, fever was the most 
common presentation in a study by Siegman-Igra (1993). Neck stiffness and other symptoms suggestive of 
meningitis were frequently absent. In the study by Chen et al (Chen H., 2005), the absence of fever, 
meningeal signs and seizures correlated with the isolation of insignificant CSF Acinetobacter isolates. Most 
cases of Acinetobacter meningitis (20 – 50%) were found to be polymicrobial (Siegman-Igra Y., 1993 ; 
Chen H., 2005).  
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g. Other clinical presentations 
 
There are a limited number of case reports of Acinetobacter endocarditis in the literature. The precise 
species identification remains an issue in these case reports (Peleg A.Y., 2008). Cases reported in the 
literature involved both native and prosthetic valves (Valero C., 1999; Starakis I., 2006; Olut A.I., 2005; 
Gradon J.D., 1992). Risk factors for gram negative infective endocarditis are diabetes mellitus type I, 
endoscopy of the gastrointestinal or genital tract, patients with congenital heart diseases, dental surgery, 
and patients with right-sided endocarditis (Krcmery V., 2010). Any breach of the integument can lead to 
Acinetobacter seeding of a heart valve (Gradon J.D., 1992). A maculopapular rash involving the palms and 
soles has been reported in cases of Acinetobacter endocarditis. Splenomegaly seems to be a common, but 
not a dominant feature of Acinetobacter endocarditis (Gradon J.D., 1992). The prognosis of Acinetobacter 
prosthetic valve endocarditis (PVE) has been more favorable than PVE due to other pathogens. This might 
be due to the low virulence of Acinetobacter species (Olut A.I., 2005).  
 
Acinetobacter can cause ulcerative keratitis and corneal ulcers. These infections may be related to the use 
of contact lenses or follow eye surgery (Kau H., 2002), (Corrigan K.M., 2001.),. There is an association 
between high levels of contamination of contact lenses with Acinetobacter and occurrence of adverse 
responses (Corrigan K.M., 2001.). Acinetobacter are not regarded as normal flora, but there is a small 
proportion of the general population that carries low numbers of this organism on their skin. Acinetobacter 
causing eye infections may have been transferred to the eye by the hands or from the hands to the contact 
lens (Corrigan K.M., 2001.).  
 
There was a single case report about a Shiga toxin-producing A. haemolyticus strain from Uruguay (Grotiuz 
G., 2006). This involved a 3-month old baby who presented with bloody diarrhea of 12 hours’ duration 
without pyrexia or other previous illnesses. Fecal samples were inoculated onto MacConkey sorbitol plates. 
All sorbitol negative colonies were recovered after 48h of incubation. These were then analyzed by PCR to 
detect the presence of shiga-toxin 1/ shiga-toxin 2(Stx 1/Stx 2) – encoding organisms. The presence of stx2 
–related sequence was then confirmed by PCR. A specially designed PCR suggested that the Shiga toxin 
genes of A. haemolyticus were carried in an infective bacteriophage. The usual enteropathogenic 
pathogens were not detected from the patient’s stool samples (Grotiuz G., 2006). 
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III. Antibiotic treatment of A. baumannii infections 
 
Peleg et al. (2008) described multidrug resistance to A. baumannii as resistance to more than two of the 
following five drug classes: ceftazidime or cefepime (antipseudomonal cephalosporins); imipenem or 
meropenem (carbapenems); ampicillin-sulbactam, ciprofloxacin or levofloxacin (fluoroquinolones), and 
gentamicin, tobramycin, and amikacin (aminoglycosides). The number of multidrug-resistant A. baumannii 
has been increasing worldwide in the past few years  (Li J., 2006). Therefore the selection of empirical 
antibiotic treatment is very challenging (Towner, 2009). This should rely on institutional-level data relating 
to the phenotypes and genotypes whenever possible. Reports in the literature that provide knowledge 
about the best therapeutic approaches with regards to Acinetobacter include in- vitro susceptibility data, 
small case series and retrospective analysis of observational studies (Towner, 2009). 
 
1. Polymyxins   
 
Due to limited treatment options, physicians have returned to the use of polymyxin B or polymyxin E 
(colistin) for the most drug-resistant Acinetobacter infections (Maragakis L.L., 2008). These antibiotics are 
cationic polypeptides that interact with the lipopolysaccharide layer of Gram-negative bacteria and are 
bactericidal against A. baumannii (Towner, 2009). Colistin exists commercially in two forms: colistin sulfate 
for oral and topical use, and colistimethate sodium for parenteral use. Both these forms can be delivered 
by inhalation  or nebulization (Towner, 2009). Nebulized forms are used in patients with nosocomial 
pneumonia.  
 
Colistin is useful for treating infections due to carbapenem-resistant isolates (Towner, 2009). A favorable 
treatment outcome with colistin in up to 76.9% of cases has been reported for all nosocomial infections due 
to multi-resistant P aeruginosa or A. baumannii (Kallel H., 2006)-. In that study by Kallel (2006), favorable 
clinical response was seen in 73.8% of cases treated for only VAP using colistin. In another study 
(Garnacho-Montero J., 2008) there was an equivalent clinical response in patients with ventilator 
associated pneumonia (VAP) treated with colistin or with imipenem according to the antibiotic susceptibility 
results of A. baumannii. In a Brazilian study (Levin A.S., 2003), a good outcome was reported in 58% of 
patients when colistin was used to treat nosocomial infections due to P. aeruginosa and A. baumannii in 
non–cystic fibrosis patients. Colistin was also found to be effective in a neutropenic rat thigh infection 
model against A. baumannii (Pantopoulou A., 2007).  
 
There are a number of studies that looked at the in vitro interaction of colistin with rifampicin against 
nosocomial strains of A. baumannii susceptible only to colistin (Giamarellos-Bourboulis E.J., 2001; Yoon J., 
2004; Pantopoulou A., 2007; Song J.Y., 2008). In one of these studies more than 50% of isolates showed 
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synergy depending on the exposure time with these two antibiotics (Giamarellos-Bourboulis E.J., 2001). 
The efficacies of colistin + rifampicin and imipenem + rifampicin combinations were also compared in a 
neutropenic mouse pneumonia model (Song J. Y., 2009). In this study colistin showed good in vitro activity 
against carbapenem resistant A. baumannii isolates and it was bactericidal at concentrations 4x MIC and 
8x MIC. The combinations of imipenem + rifampicin and colistin + rifampicin were found to be synergistic 
and bactericidal at concentrations of 1x MIC. It was recommended that rifampicin be added to either 
imipenem or colistin for the treatment of carbapenem – resistant A. baumannii infections (Song J. Y., 2009).  
 
The existing knowledge about the pharmacokinetics and pharmacodynamics of colistin is limited. The 
current dosing regimens are based on experience obtained as far back as 30 years ago (Li J., 2006). It is 
very important to administer colistin in dosages that provide maximal activity with minimal potential for the 
development of resistance (Li J., 2006). Fortunately, resistance to colistin has remained relatively low. 
Recently, heteroresistance and resistance to colistin has been reported in Australia and Korea, 
respectively (Li J., 2006; Ko K.S., 2007)). In the Australian study, resistant subpopulations of A. baumannii 
(Li J., 2006) were assumed to be responsible for the significant regrowth in the time–kill studies. The 
heteroresistance observed was unlikely to be related to previous exposure to colistin as this drug was 
never used before in the patients from whom the isolates were obtained. These subpopulations cannot be 
detected by the most commonly used commercial automated systems and the disk diffusion susceptibility 
test.  
 
Heteroresistance denotes the existence of a subpopulation, within a culture population of a susceptible 
isolate that is able to grow in a substantially high colistin concentration (Li J., 2006). From the study by Li et 
al (2006), it was demonstrated that hetero-colistin-resistant A. baumannii cannot be differentiated from 
colistin-susceptible A. baumannii by broth microdilution MIC measurement, commercial automated 
systems and disk diffusion. A population analysis profile method was used to detect the hetero-colistin-
resistant subpopulation of A. baumannii. The clinical significance of a heteroresistant subpopulation is 
unclear. It could relate to the in vivo emergence of colistin resistance after the use of the drug (Matthaiou 
D.K., 2008 ). Monotherapy with colistin for the treatment of infections due to hetero-colistin-resistant A. 
baumannii may be problematic, hence this drug should be used judiciously and appropriately (Li J., 2006).  
 
Colistin and polymyxin B resistance is rare world-wide. High colistin resistance rates in Acinetobacter 
species were reported in a Korean study (Ko K.S., 2007). Another Korean study (Park Y.K., 2009), 
suggested that most colistin-resistant Acinetobacter species isolates emerged independently. There was 
no clonal spreading of an individual bacterial clone. The mechanism of colistin resistance in Acinetobacter 
species has not been fully revealed (Park Y.K., 2009). Gram-negative organisms become resistant to 
polymyxins through adaptive mechanisms after exposure to these agents. Resistance to colistin can also 
emerge through mutational mechanisms (Matthaiou D.K., 2008 ). The former mechanism of resistance is 
unstable and regresses after the withdrawal of the antibiotics. The latter mechanism, which involves 
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mutational mechanisms, is stable and inheritable (Matthaiou D.K., 2008). In the study by Matthaiou et al 
(Matthaiou D.K., 2008), the use of colistin was found to be an independent and a strong factor associated 
with the isolation of colistin-resistant organisms. Other significant factors included the duration of colistin 
administration, inappropriate colistin dosing and duration of ICU stay (Matthaiou D.K., 2008).  
 
2. Carbapenems 
 
The carbapenems (e.g. imipenem and meropenem) have been used as the mainstay treatment for 
Acinetobacter infection up until the past few years (Towner, 2009). According to Jones et al. (Jones R.N., 
2006), imipenem is the more potent agent, compared to meropenem for the treatment of multiresistant 
Acinetobacter infection. However, in Greece it was observed that the discordance between imipenem and 
meropenem activity favors meropenem among A. baumannii isolates (Ikonomidis A., 2006). This is in 
contrast to the surveillance results of North America and Europe which established that imipenem is more 
potent than meropenem (Rhomberg P.R., 2003 ; Jones R.N., 2006). Overexpression of efflux pumps 
affects meropenem to a greater extent. Resistance to imipenem in A. baumannii is due to the presence of 
carbapenemases, such as OXA–58 and VIM–1, which hydrolyses imipenem more efficiently than 
meropenem. These carbapenemases are more prevalent in Greece (Ikonomidis A., 2006). Therefore, 
susceptibility to imipenem does not predict susceptibility to meropenem or vice versa (Maragakis L.L., 
2008). 
 
3. Sulbactam 
 
Sulbactam is a β-lactamase inhibitor with an intrinsic activity against many Acinetobacter strains. This 
intrinsic activity may be due to the ability of sulbactam to bind with penicillin-binding proteins (PBP) of 
imipenem-resistant and –susceptible isolates. Sulbactam as monotherapy is not advised for severe 
Acinetobacter infections. Commercially, sulbactam is available in combination with a β-lactam agent (e.g. 
ampicillin). This combination does not appear to contribute to activity or synergy (Maragakis L.L., 2008).  
 
There are few case reports which describe the success of sulbactam, alone or in combination with 
ampicillin for the treatment of Acinetobacter (Levin A.S., 2003; Jiménez-Mejías M.E., 1997; Smolyakov R., 
2003). In one study (Jiménez-Mejías M.E., 1997) the authors reported on clinical features and the 
outcomes of eight cases of nosocomial A. baumannii meningitis treated with ampicillin-sulbactam. The 
outcome was good in six of the eight cases. A Brazilian study looked at the clinical efficacy of the 
ampicillin-sulbactam combination for the treatment of A. baumannii. Improvement or cure rate was 67.5% 
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in that retrospective study where most patients had severe infections (Levin A.S., 2003). Ampicillin – 
sulbactam significantly decreased the risk of death in one study (p= 0.02) (Smolyakov R., 2003). In a study 
done in France (Wolff M., 1999)) involving a mouse pneumonia model caused by two different isolates of 
A. baumannii, sulbactam with the following antibiotics: imipenem; ticarcillin; ticarcillin-clavulanic acid; and 
rifampicin were tested in triple combinations: ticarcillin-sulbactam-clavulanic acid; β-lactams- sulbactam - 
rifampicin, which resulted in enhanced survival. The results from that study suggested that the use of non - 
classical combinations of β-lactams, β-lactamase inhibitors, and rifampicin should be considered during the 
treatment of nosocomial pneumonia due to A. baumannii (Wolff M., 1999).  
 
Rifampicin monotherapy leads to rapid development of resistance in vitro and in vivo. In an experimental 
pneumonia murine model, the development of rifampicin resistance was prevented by the use of rifampicin 
in combination with imipenem or sulbactam (Pachon-Ibanez M.E., 2006). The deduction from the reported 
data is that more experience with the application of sulbactam in the treatment of Acinetobacter infections 
is needed either as monotherapy or combination therapy (Giamarellou H., 2008). 
 
4. Tigecycline 
 
Tigecycline, a new class of tetracycline – related antibiotics, the glycylcyclines, was approved by the FDA 
in June 2005 (Towner, 2009; Giamarellou H., 2008; Karageorgopoulos D. E., 2008). This antibiotic is able 
to evade the major mechanisms of resistance in tetracyclines, viz. the tet (A–E) and tet (K) efflux pumps 
and the tet (M) and tet (O) determinants that provide ribosomal protection (Peleg A.Y., 2007) 2). In 
preliminary studies, tigecycline was found to have activity against several Gram-positive and Gram-
negative bacteria, including Acinetobacter (Giamarellou H., 2008)). Tigecycline antibiotic has a large 
volume of distribution, thus is able to achieve high levels in many tissue sites including the lungs. Further 
advantages are that there is no need for dosage adjustment due to age, severe renal impairment or 
hemodialysis (Giamarellou H., 2008). The FDA has approved the antibiotic only for complicated intra-
abdominal and complicated skin infections and community – acquired pneumonia (Karageorgopoulos D. 
E., 2008).  
 
Presently there is limited clinical experience with tigecycline (Towner, 2009 ; Giamarellou H., 2008)). There 
are few clinical reports about the use of tigecycline in patients infected with A. baumannii (Towner, 2009). 
One such report looked at the use of tigecycline in 34 patients with infections involving multidrug-resistant 
A. baumannii (Gordon N.C., 2009). Sixty eight percent of patients showed a positive clinical outcome. A 
poor correlation between microbiological clearance and clinical outcome was noted, mostly in patients with 
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respiratory tract infections. This was indicated by cultures which remained positive whilst the patient 
responded clinically. 
 
There is controversy surrounding the use of tigecycline for bloodstream infections (Gordon N.C., 2009); 
(Towner, 2009)). This is due to the suboptimal concentrations of tigecycline in the blood (Towner, 2009) at 
the current recommended dose (Gordon N.C., 2009). The use of tigecycline for A. baumannii bacteremia is 
not recommended if another alternative is available (Peleg A.Y., 2007).  Tigecycline is bacteriostatic 
against A. baumannii (Peleg A.Y., 2007). The development of bloodstream infection in two patients 
receiving therapeutic doses of tigecycline has been described (Peleg A.Y., 2007). These patients were 
receiving tigecycline for other indications, when they were diagnosed with A. baumannii bacteremia at 
Pittsburgh Medical Center, USA. One patient, a 76 year old woman, was on tigecycline after culturing 
vancomycin-resistant Enterococcus faecium. A. baumannii was cultured nine days later, from two blood 
cultures and a tracheal aspirate. The second patient was a 60 year old man who had a ventricular-assisted 
device inserted for ischemic cardiomyopathy. Post-operative wound sepsis developed 14 months later and 
cultures grew A. baumannii and Enterobacter cloacae. The latter organism was regarded as the significant 
one, and ertapenem was started. The patient did not respond clinically and intravenous tigecycline was 
commenced. Wound purulence decreased, showing clinical response. A. baumannii was subsequently 
grown 16 days later from two blood cultures following a new onset of fever. No susceptibilities were 
available for tigecycline. The patient did well on meropenem and amikacin, for which the isolate was 
susceptible. This report raised the question about the use of tigecycline to treat A. baumannii bacteremia 
as both patients developed A. baumannii infections whilst on tigecycline. Multidrug efflux pumps may be 
responsible for the tigecycline non-susceptibility in Acinetobacter (Peleg A.Y., 2007). Over 50% of patients 
treated for A. baumannii bacteremia had a positive outcome in one study (Gordon N.C., 2009). The 
explanation was the eradication of the underlying source of infection. Also, there could have been synergy 
between tigecycline and other antibiotics which were used (Gordon N.C., 2009).  
 
A group in Italy looked at the in vitro activity of tigecycline in combination with various antibiotics against 
multidrug - resistant A. baumannii (Principe L., 2009). They demonstrated the in vitro synergy of tigecycline 
in combination with colistin, levofloxacin, amikacin and imipenem. This synergy was only observed among 
tigecycline non-susceptible strains (Principe L., 2009). According to the authors, more studies are needed 
to clarify the molecular mechanisms involved in synergy between tigecycline and other antibiotics (Principe 
L., 2009). 
 
High tigecycline resistance in multidrug–resistant multiple clones of A. baumannii has been reported when 
E-test and disk diffusion methods were used (Navon-Venezia S., 2007). In that study, 60% of the isolates 
were resistant to tigecycline, 12% were intermediate and 22% were susceptible (Navon-Venezia S., 2007). 
This high tigecycline resistance could be due to the methods used, disk diffusion method and E-test 
(Thamlikitkul V., 2007)). In a study done in Thailand, there was a discrepancy in susceptibility results of 
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tigecycline against Acinetobacter species when different methods were used. The E- test method tends to 
give 4-fold higher MICs than those determined by the broth microdilution method. According to the authors, 
the E-test method might not be accurate in testing of tigecycline against Acinetobacter spp. (Thamlikitkul 
V., 2007). 
 
IV. Combination therapy 
 
Antibiotic combinations are used mostly as empirical therapy in critically ill patients with possible 
polymicrobial infections. One rationale for the use of combination therapy is to achieve synergy which 
increases the activity of either antibiotic. Synergy implies that significantly greater activity is provided by the 
two antibiotics combined than that provided by the sum of each antibiotic alone. Another rationale is to 
administer lower doses of either antibiotic to decrease their toxicity. Combination therapy has also been 
used to prevent the development of resistance to either antibiotic.  
 
There are a number of ways that antibiotics may interact (Moellering, 1979). Some of the mechanisms 
involved in synergistic effects include sequential blockade of a given metabolic pathway (e.g. in the use of 
trimethoprim and sulfonamides); one drug causing changes in the bacterial surface, allowing better 
penetration of the second prescribed drug (e.g. in enterococci: penicillin and aminoglycoside combinations; 
vancomycin with an aminoglycoside) and inhibition of an enzyme responsible for antibiotic inactivation (e.g. 
clavulanic acid and amoxicillin combination).  
 
Antibiotic combinations which have been found to be synergistic in vitro have been used clinically in the 
treatment of patients with neutropenic sepsis and in the treatment of enterococcal endocarditis (Eliopoulos 
G.M., 1982). Combination therapy is also used in the empirical treatment of patients with sepsis to provide 
initial broad antibiotic cover against the most common Gram positive and Gram negative organisms and to 
treat polymicrobial infections e.g. brain abscesses, intra-abdominal, pelvic, and necrotizing lung infections 
(Klastersky J., 1982). Another clinical rationale for the use of antibiotic combinations is to prevent the 
development of resistance e.g. in tuberculosis treatment. Combining antibiotics prevents the emergence of 
resistant strains, which might have occurred rapidly if a single antibiotic was used. 
 
The following combinations have been shown to provide enhanced activity against strains of A. baumannii: 
colistin plus rifampicin; polymyxin B plus rifampicin plus imipenem; rifampicin plus imipenem, tobramycin or 
colistin; rifampicin plus sulbactam/ampicillin, colistin plus minocycline; imipenem plus sulbactam, colistin 
plus tigecycline; (Yoon J., 2004; Montero A.; 2004; Tripodi M., 2007; Song J.Y., 2008)  In most of these 
cases, the mechanism of positive interaction is unknown. In one study, it was suggested that the probable 
role of polymixin B was its rapid permeabilization of the outer membrane, allowing enhanced penetration 
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and activity of imipenem and rifampicin (Yoon J., 2004). Data regarding the best combinations for synergy, 
as mentioned above, is mostly derived from in vitro and in vivo animal studies (Karageorgopoulos D. E., 
2008). The good results obtained from these studies do not necessarily correlate with clinical findings 
(Karageorgopoulos D. E., 2008). Clinical trials are too few to recommend the use of specific combinations 
for the treatment of multidrug-resistant A. baumannii (Towner, 2009; Karageorgopoulos D. E., 2008). 
 
Timurkaynak et al (Timurkaynak F., 2006) used the checkerboard method to determine whether 
combinations of colistin, rifampicin, meropenem, azithromycin and doxycycline act synergistically against 
multidrug-resistant strains of Pseudomonas aeruginosa and A. baumannii. Five strains of A. baumannii 
were selected based on differences in colistin MICs. The combination of colistin and rifampicin was fully 
synergistic against four A. baumannii strains. When time-kill studies were used by Giamarellos-Bourboulis 
et al to assess the interaction of colistin and rifampicin on multidrug-resistant A. baumannii, the activity of 
colistin was increased in the presence of rifampicin (Giamarellos-Bourboulis E.J., 2001). 
 
Song et al (Song J.Y., 2008) retrospectively evaluated the safety and effectiveness of a combination of 
colistin and rifampicin in 10 patients with ventilator-associated pneumonia caused by carbapenem-resistant 
(only susceptible to colistin) A. baumannii. The mean duration of colistin/rifampicin therapy was 8.1 ± 1.8 
days. With regard to clinical outcome, 70% (7 patients) of the patients benefitted from the combination of 
colistin + rifampicin. Six patients showed microbiological eradication of follow-up cultures taken after seven 
days of colistin/rifampicin. When Saballs et al (Saballs M., 2006) treated 10 patients with different 
infections caused by carbapenem-resistant A. baumannii with 6 – 21 days of imipenem/rifampicin 
combination, seven patients were clinically cured. The cure rates between the study by Song et al and 
Saballs et al were similar, but high-level rifampicin resistance (MIC = 256 mg/l) developed in seven 
patients during treatment in the latter study. The MICs of rifampicin were not changed in the former study. 
The differences could be due to differences in antibiotic combinations or infectious diseases (Song J.Y., 
2008). 
 
In a mouse pneumonia model by Montero et al, the combination of imipenem + tobramycin was the most 
active combination against moderately carbapenem-resistant (MIC 8 mg/l) A. baumannii. In infections 
caused by highly carbapenem-resistant (MIC 512 mg/l) strain rifampicin + imipenem and rifampicin + 
tobramycin were the most active combinations. According to the investigators, imipenem can still be used 
against A. baumannii with moderate levels of imipenem resistance, preferably in combination with 
aminoglycosides. For A. baumannii strains with high resistance to imipenem, a combination of rifampicin 
with imipenem, tobramycin or colistin may be useful, only if resistance to rifampicin is moderate (Montero 
A., 2004). 
 
 20
Yoon et al (Yoon J., 2004) looked at in vitro double and triple synergistic activities of polymyxin B, 
imipenem, and rifampicin against multidrug-resistant A. baumannii by checkerboard method. The 
combination of polymyxin B + imipenem, polymyxin B + rifampicin, and polymyxin B, imipenem, and 
rifampicin demonstrated synergy. Polymyxin B + imipenem and polymyxin B + rifampicin were bactericidal 
for seven of eight isolates within 24 hour.  
 
In the in vitro comparative study by Tripodi et al (Tripodi M., 2007), the activity of colistin, rifampicin, 
imipenem and sulbactam/ampicillin alone and in combination against multidrug-resistant A. baumannii was 
evaluated by time-kill studies.  Bactericidal effect was shown for colistin but not for imipenem, rifampicin or 
sulbactam/ampicillin used as single agents. The combination of rifampicin + imipenem or 
sulbactam/ampicillin was synergistic for all isolates. colistin + rifampicin were only synergistic in the study 
for isolates showing higher minimum inhibitory concentrations for rifampicin. 
 
 
V. In vitro techniques for measuring antibiotic synergism 
 
Synergistic antibiotics are often used to treat serious infections (Berenbaum M.C., 1978) particularly in 
immunosuppressed or granulocytopenic patients (Norden C.W., 1979). Two traditional methods that have 
been used for synergy testing are the checkerboard and time kill (killing curve) methods. The time-kill 
method measures the rate of bacterial killing by antibiotics (Norden C.W., 1979).The checkerboard method 
examines the ability of antibiotic combinations to inhibit growth of an organism. The checkerboard method 
is one of the most frequently used techniques to assess drug interactions. The term checkerboard arises 
from the pattern that is generated by the multiple dilutions of the two antibiotics being tested.  
 
Historically, the checkerboard method was performed in an array of tubes using broth macrodilution. This 
was cumbersome, time consuming and expensive. Presently, testing is done using microtiter trays. The 
results are calculated mathematically and expressed in terms of a fractional inhibitory concentration (FIC) 
index. This is equal to the sum of the FICs for each drug. The FIC for a drug is defined as the minimal 
inhibitory concentration (MIC) of the drug in combination divided by the MIC of the drug used alone. If the 
FIC index is ≤ 0.5, the antibiotic combination is interpreted as being synergistic; FIC index >0.5 and ≤1.0 
as additive (Timurkaynak F., 2006), between 1 and 4 as indifferent and > 4 as antagonistic (Schwalbe R., 
2007). 
The Epsilometer (E-test) is a relatively new agar diffusion method for antimicrobial susceptibility testing 
(Arroyo L. A., 2009; Bonapace C.R., 2000). It is a preformed and predefined gradient of antibiotic 
concentrations immobilized in a dry format onto the surface of a plastic strip. The continuous concentration 
gradient is calibrated across a corresponding MIC range covering 15 twofold dilutions. When applied to the 
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surface of an inoculated agar plate, the antibiotic on the E-test strip is instantaneously transferred to the 
agar in the form of a stable and continuous gradient directly beneath and in the immediate area of the strip. 
A number of investigations have documented E-test performance to be equivalent to reference MIC 
methods with a high degree of reproducibility in most laboratory settings (Schwalbe R., 2007). 
 
The E-test overlay method is a modification of this method to determine synergy between different 
antibiotics. The E-test strip of the first antibiotic to be tested is placed on an agar plate inoculated with the 
test organism. The plate is then incubated at room temperature for 1 hour. The E-test strip is then lifted off 
the agar surface and replaced with the strip of the second antibiotic. This is placed exactly on top of the 
gradient of the first antibiotic. The plate is incubated for 24 hours at 37 °C. The fractional inhibitory 
concentrations (FIC) are calculated to evaluate the effect of the antibiotic combination. Interpretation of 
results is as for the checkerboard method. The E-test overlay method is easy to perform, flexible and time 
efficient (Manno G., 2003; Haddad F.A., 2005).  
 
Haddad et al (Haddad F.A., 2005) evaluated antibiotic combinations against multidrug-resistant A. 
baumannii using the E-test overlay method. This method was found to be less labor-intensive. It also has a 
high correlation with the checkerboard method. Manno et al (Manno G., 2003) assessed synergy of various 
combinations of antibiotics against 131 isolates of Burkholderia cepacia complex using the E-test overlay 
method. The agreement between the E-test and checkerboard methods was 90%. In a Turkish study by 
Kocazeybek et al (Kocazeybek B.S., 2002), various antibiotic combinations were investigated using the E-
test overlay method in multiresistant P. aeruginosa. The agreement rate between the E-test and 
checkerboard method was 100%. The E-test method was evaluated as a good alternative for combination 
investigation due to its ease of application and evaluation and also for its good agreement in that study with 
the checkerboard method (Kocazeybek B.S., 2002). 
 
White et al (White R.L., 1996) and Bonapace et al (Bonapace C.R., 2000) compared antibiotic synergy by 
E-test, time kill, and checkerboard methods. There was poor agreement between the E-test and other 
methods in these studies. This can be attributed to improper methodology inconsistent with the 
manufacturer’s recommendations on use of the E-test method for synergy testing (Haddad F.A., 2005). In 
these two studies the E-test strips were placed on the Muller-Hinton agar in a cross formation, with a 900 
angle at the intersection between the scales at their respective MICs for the organism. 
 
The E-test overlay method has also been compared to checkerboard and time-kill methods for synergy 
testing of antifungal agents against Candida species (Lewis R.E., 2002). The agreement between the E-
test and checkerboard methods was poor. Overall, agreement between E-test and time-kill studies was 
good. Of the three methods, E-test was the simplest to use and yielded reproducible results for testing 
antifungal combinations (Lewis R.E., 2002). 
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VI. Aim of the study 
 
The aim of this study is to assess the in vitro activity of different combinations of colistin, rifampicin, 
imipenem and tobramycin against selected clinical strains of A. baumannii from patients in a tertiary 
hospital using, the checkerboard and E-test synergy methods. . 
Objectives 
 
• To compare E-test and broth dilution MIC testing methods 
• To determine if the following antibiotic combinations exhibit in vitro synergy against Acinetobacter 
baumannii isolates with different antibiotic susceptibility profiles, including multi-drug resistant 
(MDR) A. baumannii: 
  Colistin (col) + rifampicin (rif) 
  colistin + imipenem (imi) 
  colistin + tobramycin (tob) 
  rifampicin + tobramycin 
  rifampicin + imipenem 
  imipenem + tobramycin 
   
• To evaluate the E test synergy method using the checkerboard method as a reference standard. 
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VII. Material and Methods 
Study design: 
 
This is a descriptive study that was conducted at the NHLS Medical Microbiology laboratory which is 
situated at Tygerberg Hospital, Cape Town. The laboratory is a P2 facility with adequate infrastructure. 
Safety precautions were adhered to according to the laboratory safety manual.  Ethical approval was 
obtained from the Committee of Human Research of Stellenbosch University (ethics number: N08/02/037). 
 
Bacterial strains: 
 
Acinetobacter baumannii isolates were collected from all routine clinical specimens over a six month period 
from January 2008 – June 2008.  
Personal information of patients from which isolates were obtained remained anonymous by coding isolate 
samples to ensure confidentiality. A total of 50 isolates, identified by the automated Vitek 2 analyzer 
(Biomerieux), were collected. Strains were selected randomly, based on specific antibiotic sensitivity 
patterns representing strains which were very resistant (only colistin and tobramycin sensitive) and those 
that were fully sensitive to all tested antibiotics. Each isolate was stored in cryobroth at -80°C for 
subsequent synergy testing. Stored isolates were subcultured twice on two successive days on blood agar 
prior to in vitro testing. Only one isolate from each patient per admission period was included in this study.  
 
Selection of isolates for further MIC determinations and synergy testing: 
 
All isolates were identified by the automated Vitek 2 system. Susceptibility testing was done by disk 
diffusion method for imipenem and tobramycin due to limitations of the Vitek susceptibility method for 
Acinetobacter testing. Colistin susceptibility was determined by the E-test method as only identification of 
the selected isolates was done by Vitek 2.system at that time. Rifampicin does not form part of the panel for 
routine testing of A. baumannii. The isolates were then grouped according to their antibiotic profiles. Ten 
isolates were purposely selected based on the antibiogram patterns of tobramycin, colistin and imipenem. 
Due to time constraints and the labor intensiveness of the procedure, only selected isolates were tested 
with the checkerboard method. Three isolates were sensitive to tobramycin and resistant to imipenem 
(isolates 1, 23, and 25); three were sensitive to imipenem and resistant to tobramycin (isolates 14, 16, and 
17); two isolates were both resistant to imipenem and tobramycin (isolates 3 and 6) and two isolates (9 and 
30) were sensitive to both imipenem and tobramycin. All ten isolates were sensitive to colistin.  
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Determination of minimum inhibitory concentrations (MICs): 
 
MICs of the ten selected isolates were determined in triplicate by the E-test method according to the 
manufacturer’s instructions (AB Biodisk, Solna, Sweden) and the broth microdilution method according to 
the Clinical Laboratory Standards Institute (CLSI) recommendations (CLSI Document M7-A7, 2006). The 
concentrations of the E-test strips (AB Biodisk, Solna, Sweden) were 0.016 – 256 µg/ml for colistin, 
tobramycin 0.064 – 1024 µg/ml, and for rifampicin and imipenem was 0.002 – 32 µg/ml. The final 
concentrations tested by broth microdilution were 0.064 – 32 μg/ml, for colistin (Sigma-Aldrich, USA), 
rifampicin (Sigma-Aldrich, USA) and imipenem (Abtek biological ltd, Liverpool, UK), and 0.125 – 64 μg/ml 
for tobramycin (Sigma-Aldrich, USA). The lowest concentration of antibiotic that showed no growth was 
recorded as the MIC. The susceptibility of colistin, imipenem, and tobramycin were interpreted according to 
CLSI guidelines (CLSI Document M100-S20, 2010). The susceptibility breakpoint for rifampicin was 
established as ≤ 2 μg/ml, based on a previous study by Hogg et al (1998). 
 
Comparison of the E-test and broth microdilution susceptibility methods 
 
The MIC results were interpreted as susceptible, intermediately-resistant or resistant according to the CLSI 
criteria. Discrepancies in the results were characterized as very major, major or minor errors 
very major error broth dilution result resistant and E-test or disc diffusion result susceptible  
(false-susceptible) 
major error       broth dilution result susceptible and E-test or disc diffusion result resistant  
(false-resistant) 
minor error       broth dilution result resistant or susceptible and E-test or disc diffusion result 
intermediately resistant or vice versa 
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Synergy testing: 
 
The following antibiotic combinations were tested with the E-test (all ten isolates in triplicate) and 
checkerboard synergy methods (three isolates tested in duplicate): colistin + rifampicin; colistin + 
imipenem; colistin + tobramycin; rifampicin + tobramycin;  rifampicin + imipenem and imipenem + 
tobramycin. 
The antibiotic combinations were chosen based on published data and the easy availability of these 
antibiotics in our hospital. The median MIC value obtained for each antibiotic with the broth microdilution 
method was used to determine the MIC dilutions in the checkerboard method. 
 
 
E-test synergy method: 
 
Mueller-Hinton agar plates were inoculated with swabs saturated with suspensions of the test organism 
equivalent to a 0.5 McFarland standard. The E-test strip of antibiotic A was placed on the inoculated agar 
surface for one hour at room temperature. After one hour, the strip was removed and the E-test strip of 
antibiotic B was placed on top of the imprint of the first strip which was then incubated at 35°C for 24h as 
described previously (Manno G., 2003).  E-test strips were handled by using an E-test vacuum pen (Nema 
C88 – AB BioMerieux-Sweden). The MIC was interpreted as the value at which the inhibition zone 
intersected the scale on the E-test strip. 
 
Calculation of fractional inhibitory concentration index (FIC Index): 
FIC (FIC index) = FIC drug A + FIC drug B = MICAB/MICA + MICBA/MICB  
FIC of antibiotic A = MIC of antibiotic A in combination with antibiotic B /MIC of antibiotic A alone 
FIC of antibiotic B = MIC of antibiotic B in combination with antibiotic A /MIC of antibiotic B alone 
 
 
The results were interpreted as follows: 
FIC index ≤0.5, synergistic; 
FIC index >0.5 and ≤1.0, additive 
FIC index >1.0 and ≤4, indifferent  
FIC index > 4, antagonistic 
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Checkerboard synergy method: 
The checkerboard method was performed according to the method described by Schwalbe (2007). 
Preparation of checkerboard microdilution panels 
The number of combination panels that had to be prepared was determined: one for each isolate, and one 
panel for the dilution of the second antibiotic. 
Antibiotic powders used were colistin sulfate salt (Sigma-Aldrich, USA), tobramycin (Sigma-Aldrich, USA), 
imipenem (Abtek biological ltd, Liverpool, UK), and Rifampicin (Sigma-Aldrich, USA). The latter antibiotic 
was stored in a foil, both in powder and solution forms because of its photosensitivity. Sufficient quantities 
of antibiotic solutions were prepared. The concentration of antibiotic prepared prior to dilution was four 
times higher than the highest concentration to be tested. For example, if the initial concentration for 
antibiotic A was 512 μg/ml and for antibiotic B was 64 μg/ml, then it was necessary to start with a 
concentration of 2 048 μg/ml for antibiotic A and 256 μg/ml for antibiotic B. The median MICs determined 
with the broth dilution method (appendix A) were used to configure the concentrations to be used in the 
checkerboard panels (see figure 2, below). 
For each panel, the following quantities of antibiotic solutions were required: 
a. antibiotic A : 16 wells x 0.05ml = 0.8 ml 
b. antibiotic B : 24 wells x 0.05ml = 1.2ml 
For one isolate: 
Two panels were prepared; one for the combination drug panel (panel 1) and the other (panel 2) was used 
for making antibiotic dilutions for the second antibiotic (antibiotic B) 
For panel 1(see figure 1, below):  
a. 50 μl of sterile Cation-supplemented Muller-Hinton broth (CSMHB) was dispensed into every well except 
those of column 1 and column 12 
b. 50 μl of sterile CSMHB was added to G12 
c. 50 μl of antibiotic solution A was added to wells A12 – G12 and wells A11 – H11. 
d. serial dilutions were made from column 11 to column 2 and 50 μl discarded from column 2 
e. 50 μl were taken from B1 – B11 from panel 2 and dispensed in the corresponding row of panel 1. 
f. step e was repeated for the next higher concentration 
For panel 2: 
a. 100 μl of CSMHB was dispensed into every well except those of row A and row H 
b. 100 μl of antibiotic solution B were added to H1 – H11 and G1 – G12 
c. serial dilutions were made from each well in row B (the final volume in each well is 100 μl (0.1ml) 
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the prepared panels were stored at -800C overnight. The trays were covered with lids and placed in sealed 
plastic bags 
 
Figure 2: an example of a worksheet template for broth microdilution checkerboard panel (Reproduced 
from Schwalbe et al., 2007) 
 
Preparation of inoculum: 
Frozen stored isolates were subcultured twice on two successive days onto blood agar media to obtain 
fresh cultures for synergy testing. Three to five colonies of the selected isolate were touched with a sterile 
swab and then transferred to 5 ml of sterile CSMHB to make a 0.5 McFarland standard (1.5 x 108 CFU/ml) 
A total of at least 5ml of diluted inoculum was required for one panel, including sufficient excess volume for 
the reservoir 
0.1ml of the adjusted inoculum suspension was added to 9.9 ml of sterile CSMHB (1:100 dilution) to 
achieve approximately 106 CFU/ml 
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Inoculation and incubation of checkerboard panel: 
50 μl of the diluted inoculum was added to every well except H12, using a multichannel pipette 
50 μl of the diluted inoculum was added to growth control well A1 
A purity blood agar plate was inoculated by subculturing 0.001 ml of inoculum from the reservoir onto a 
blood agar plate using a 1-μl loop 
An inoculum verification plate was prepared as follows: 
a. 50 μl of diluted inoculum was added to 0.45ml of sterile 0.85% saline  
(dilution 10-1) 
b. 0.1ml was transferred from dilution 10-1 to 0.9 ml of sterile 0.85% saline and vortexed well (dilution 
10-2) 
c. 0.1 ml was transferred from dilution 10-2  to 0.9ml of sterile 0.85% saline and vortexed well (dilution 
10-3) 
d. 0.1ml of dilution10-3 was plated onto a blood agar plate and spread for quantitation by streaking in 
several directions with a sterile loop 
The trays were placed in plastic bags and incubated at 350C for 20h 
The purity and inoculum verification plates were incubated at 350C for 20h. 
 
Reading MIC panels 
For each panel, the growth control well is examined for heavy turbidity to determine organism viability.  The 
purity plates are also examined to check that cultures do not show mixed growth. Growth or no growth was 
recorded with the help of a viewing device for all the wells as shown on the worksheet (see Appendix C for 
an example of a worksheet)  
The MICs for the individual antibiotics in the checkerboard method was read as follows: 
MIC of antibiotic A: row A – lowest concentration showing inhibition of growth 
MIC for antibiotic B: column 1 - lowest concentration showing inhibition of growth 
These MICs were used in the formula to calculate the FIC indices. Several combination concentrations 
were tested along the checkerboard and multiple FIC indices are therefore calculated. The FIC index was 
worked out from rows in the middle with most reaction. Synergism or antagonism is reported even if 
exhibited only once within the checkerboard.  
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Definition of terms 
 
• Synergy – the result with the combination is significantly better than the sum of their independent 
activities when measured separately; the MIC of the combination is ≥ 2 dilutions LOWER than MIC 
of the most active drug alone 
• Additive - An additive combination of two drugs  produce the same effect as the combination (the 
equally effective concentrations), when the agents are used alone 
• Indifferent – the result with two drugs is equal to the best individual result;  the MIC of the 
combination is within ± 1 dilution compared to the most active drug alone 
• Antagonism – the result of the combination is significantly less than the best individual result; the 
MIC of the combination is ≥ 2 dilutions higher than the MIC of the most active drug alone. 
 
Quality control: 
 
The following quality control strains were used for MIC testing only, as recommended by the Clinical 
and Laboratory Standard Institute (CLSI, 2006). There are no CLSI criteria for interpretation with 
synergy methods for these quality control strains. The QC strains were used just for the E-test and 
broth dilution MICs, and not for synergy testing. See  Appendix C for an example of a worksheet 
template for broth microdilution checkerboard panel  
a. Escherichia coli ATCC 25922 
b. Pseudomonas aeruginosa ATCC 27853 
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VIII. Results: 
Determination of MICs and comparison of susceptibility methods: 
 
The MICs obtained with the E-test and broth microdilution methods are shown in appendix A (tables 1-8). 
Both methods were done in triplicate for the 10 selected isolates. With both methods, all isolates were 
sensitive to colistin. The MICs for the control microorganisms were within the expected ranges. The number 
of colonies on the inoculum verification plates was counted, and was between 75 and 150. 
 
All isolates were resistant to rifampicin by E-test method (Table 3, Appendix A) (MICs, 4 – 8 µg/ml; 
resistance breakpoint ≤2 µg/ml) (Hogg G. M., 1998). However, by broth microdilution seven isolates tested 
susceptible (2-3 double dilutions lower than E-test MICs). These constituted major errors (broth 
microdilution susceptible, E-test false resistant).   
 
With imipenem, minor errors were found in only two isolates, testing intermediate resistant with the E-test 
method and resistant with the broth microdilution method. Excellent categorical agreement was obtained 
with the other isolates.  
 
With tobramycin, discrepancies were found in two isolates, one testing susceptible with the E-test method, 
but resistant with broth microdilution method (very major error) and one testing intermediate with E-test, but 
susceptible with broth microdilution method (minor error).  
 
Table 9 (Appendix A) shows the MIC median values and their interpretative categories for colistin, 
rifampicin, imipenem, and tobramycin by both the E-test and broth microdilution methods. The results of the 
disk diffusion for imipenem and tobramycin as tested in the routine microbiology laboratory are also 
presented for comparison. With imipenem, the disk diffusion method gave one very major error. With 
tobramycin, the disk diffusion method showed discrepant results for the same two isolates as found with the 
E-test method, as well as further discrepant results in two other isolates (1 very major and 3 major errors). 
 
Overall good reproducibility was obtained with all three methods. The agreement of MICs between the 
broth dilution and E-test methods was good with not more than 2 dilution differences in MIC values for all 
isolates. The E-test MICs matched the broth microdilution MICs or differed by 1 double dilution in 73% of 
tests. However, the categorical agreement between the methods for rifampicin was poor. Although MICs 
did not differ with more than two dilutions in most cases, many major errors occurred because the MICs 
clustered around the breakpoints. 
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MICs of antibiotic combinations with E-test combination testing:  
The MICs obtained for the respective antibiotic combinations with the E-test combination testing method is 
shown in appendix B, Tables 1-10. For all ten isolates, combination testing was done in triplicate and 
showed good reproducibility. The median MIC values obtained for the combinations were used for the 
calculation of the FIC index.  
 
 
Results of the E-test combination testing method: 
The following tables (Tables 1-6) show the median MICs obtained with the E-test method for the respective 
antibiotic combinations. The FIC index was calculated and interpreted according to the formula described in 
the methods chapter. For isolates with MICs above the upper threshold concentration tested, the FIC index 
could not be calculated as the exact MIC was not determined. The combinations of colistin + rifampicin, 
colistin + imipenem, colistin + tobramycin, rifampicin + tobramycin, rifampicin + imipenem, and imipenem + 
tobramycin all showed indifferent or additive results. No synergistic results were obtained by the E-test 
method for all the above-mentioned combinations. There was one antagonistic result for the combination of 
colistin + tobramycin (isolate 16). 
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Table 1: Antibiotic combination MICs and FIC index – E-test method 
Col + rif 
Isolate MIC col 
(µg/ml) 
MIC col + 
rif 
MIC rif 
(µg/ml) 
MIC rif + 
col 
FIC 
index 
interpretation 
1 0.5 0.5 4.0 0.032 1.008 indifferent 
3 1.0 1.0 4.0 0.125 1.031 indifferent 
6 1.0 1.0 8.0 0.125 1.016 indifferent 
9 0.5 1.0 8.0 0.064 2.008 indifferent 
14 1.0 1.0 4.0 0.064 1.016 indifferent 
16 0.5 0.5 4.0 0.064 1.016 Indifferent 
17 0.5 0.5 4.0 0.064 1.016 indifferent 
23 1.0 0.5 4.0 0.064 0.516 additive 
25 1.0 0.5 4.0 0.064 0.516 additive 
30 1.0 1.0 4.0 0.125 1.031 indifferent 
 
FIC, fractional inhibitory concentration; Col, colistin; Rif, rifampicin; Imi, imipenem; Tob, tobramycin 
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Table 2: Antibiotic combination MICs and FIC index – E-test method 
Col + imi 
Isolate MIC col 
(µg/ml) 
MIC col 
+imi 
MIC imi 
(µg/ml) 
MIC imi + 
col 
FIC 
index 
interpretation 
1 0.5 1.0 8.0 0.125 2.016 indifferent 
3 1.0 1.0 8.0 0.125 1.016 indifferent 
6 1.0 1.0 16.0 0.125 1.009 indifferent 
9 0.5 1.0 0.25 0.125 2.5 indifferent 
14 1.0 1.0 0.25 0.125 1.5 Indifferent 
16 0.5 1.0 0.25 0.25 3.0 indifferent 
17 0.5 1.0 0.25 0.25 3.0 indifferent 
23 1.0 0.5 32 0.25 0.509 additive 
25 1.0 1.0 >32 0.125 ND ND 
30 1.0 1.0 >32 0.125 ND ND 
ND = not determined 
 
 34
Table 3: Antibiotic combination MICs and FIC index – E-test method 
Col + tob 
 
Isolate MIC col 
(µg/ml) 
MIC col + 
tob 
MIC tob 
(µg/ml) 
MIC tob 
+ col 
FIC 
index 
interpretation 
1 0.5 1.0 4.0 1.0 2.25 indifferent 
3 1.0 1.0 128 1.0 1.008 indifferent 
6 1.0 2.0 2.0 1.0 2.5 indifferent 
9 0.5 0.5 1.0 1.0 2.0 indifferent 
14 1.0 1.0 8.0 1.0 1.125 indifferent 
16 0.5 2.0 4.0 4.0 5.0 antagonistic 
17 0.5 0.5 16 1.0 1.063 indifferent 
23 1.0 1.0 2.0 0.5 1.25 indifferent 
25 1.0 0.5 1.0 1.0 1.5 indifferent 
30 1.0 0.5 2.0 1.0 1.0 additive 
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Table 4: Antibiotic combination MICs and FIC index – E-test method 
Rif + tob 
Isolate MIC rif 
(µg/ml) 
MIC rif + 
tob 
MIC tob 
(µg/ml) 
MIC tob + 
rif 
FIC 
index 
interpretation 
1 4.0 0.5 4.0 4.0 1.125 indifferent 
3 4.0 4.0 128 32 1.25 indifferent 
6 8.0 0.5 2.0 4.0 2.063 indifferent 
9 8.0 0.125 1.0 1.0 1.016 indifferent 
14 4.0 2.0 8.0 8.0 1.5 indifferent 
16 4.0 0.5 4.0 4.0 1.125 indifferent 
17 4.0 2.0 16 16 1.5 indifferent 
23 4.0 0.5 2.0 1.0 0.625 additive 
25 4.0 0.125 1.0 1.0 1.031 indifferent 
30 4.0 0.125 2.0 2.0 1.031 indifferent 
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Table 5: Antibiotic combination MICs and FIC index – E-test method 
Rif + imi 
 
Isolate MIC rif 
(µg/ml) 
MIC  rif + 
imi 
MIC imi 
(µg/ml) 
MIC imi +  
rif 
FIC 
index 
interpretation 
1 4.0 4.0 8.0 4.0 1.5 indifferent 
3 4.0 4.0 8.0 4.0 1.5 indifferent 
6 8.0 8.0 16.0 4.0 1.25 indifferent 
9 8.0 0.25 0.25 0.25 1.031 indifferent 
14 4.0 0.25 0.25 0.25 1.063 indifferent 
16 4.0 0.5 0.25 0.25 1.125 indifferent 
17 4.0 0.5 0.25 0.25 1.125 indifferent 
23 4.0 8.0 32 4.0 2.125 indifferent 
25 4.0 4.0 >32 8.0 ND ND 
30 4.0 4.0 >32 4.0 ND ND 
ND= not determined 
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Table 6: Antibiotic combination MICs and FIC index – E-test method 
Imi + tob 
 
Isolate MIC imi 
(µg/ml) 
MIC imi+ 
tob 
MIC tob 
(µg/ml) 
MIC tob 
+ imi 
FIC 
index 
interpretation 
1 8.0 0.5 4.0 4.0 1.06 indifferent 
3 8.0 8.0 128 64 1.5 indifferent 
6 16.0 0.25 2.0 2.0 1.016 indifferent 
9 0.25 0.125 1.0 1.0 1.5 indifferent 
14 0.25 0.25 8.0 4.0 1.5 indifferent 
16 0.25 0.25 4.0 2.0 1.5 indifferent 
17 0.25 0.25 16 4.0 1.25 indifferent 
23 32 0.25 2.0 1.0 0.508 additive 
25 >32 0.125 1.0 1.0 ND ND 
30 >32 0.064 2.0 2.0 ND ND 
ND= not determined 
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Results of the checkerboard method: 
The following tables (Tables 7-12) show the MICs and FIC indices obtained with the checkerboard method 
for the respective antibiotic combinations. This method was done on selected isolates. The selection was 
based on broth dilution MICs (median values) of the respective antibiotics. These median MICs were also 
used to configure the antibiotic concentrations in the checkerboard microdilution panels (see  Appendix C 
for an example of a worksheet). The MICs for the individual antibiotics as determined in the checkerboard 
(row A for antibiotic A and column one for antibiotic B) were used in the formulae to calculate the FIC 
indices.  For col + rif combination, rifampicin susceptible isolates and one resistant isolate (isolate 3) was 
selected. Only those isolates susceptible to imipenem were selected for the checkerboard method in the col 
+ imi combination. Isolate 9 was done in duplicate to assess reproducibility. For the col + tob combination, 
only the tobramycin susceptible isolates were selected. For rif + tob combination, three isolates susceptible 
to both antibiotics, two resistant to both antibiotics and three isolates resistant to rif, but susceptible to tob 
were chosen.  For the rif + imi, and imi + tob combinations, four isolates susceptible to imi were tested 
Some isolates were tested in duplicate to check for reproducibility of this method. The FIC index was 
calculated and interpreted according to the formula described in the methods chapter. Synergistic results 
were observed in four of the six isolates for which the combination of colistin and rifampicin was tested. The 
other two isolates showed indifferent/additive results. All the other combinations showed indifferent/additive 
results for all isolates except isolate 30 (col + tob) and isolate 25 (rif + tob) which showed synergism. No 
antagonistic results were observed by the checkerboard method. 
 
Table 7: Antibiotic combination MICs and FIC index - checkerboard method 
Col + rif 
Isolate MIC col 
(µg/ml) 
MIC col + 
rif 
MIC rif 
(µg/ml) 
MIC rif + 
col 
FIC 
index 
interpretation 
1 0.125 0.125 1.0 0.125 1.125 indifferent 
3 0.5 0.064 16 1.0 0.191 synergistic 
6 0.5 0.064 2 0.125 0.253 synergistic 
16 0.25 0.125 2.0 1.0 1.0 additive 
23 0.125 0.032 1.0 0.125 0.381 synergistic 
30 0.25 0.032 1.0 0.064 0.192 synergistic 
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Table 8: Antibiotic combination MICs and FIC index - checkerboard method (isolate 9 done in duplicate) 
Col + imi 
Isolate MIC col 
(µg/ml) 
MIC col+imi MIC imi 
(µg/ml) 
MIC imi+col FIC 
index 
interpretation 
9a 0.125 0.064 0.125 0.064 1.024 indifferent 
9b 0.125 0.064 0.125 0.032 0.768 additive 
16 0.125 0.064 0.125 0.064 1.024 indifferent 
17 0.5 0.5 0.125 0.032 1.256 indifferent 
 
 
Table 9: Antibiotic combination MICs and FIC index - checkerboard method 
Col + tob 
 
Isolate MIC col 
(µg/ml) 
MIC col+tob MIC tob 
(µg/ml) 
MIC tob+col FIC 
index 
interpretation 
9 0.25 0.125 0.25 0.125 1.0 additive 
14 0.125 0.125 1.0 0.5 1.5 indifferent 
16 0.125 0.064 8.0 4.0 1.012 Indifferent 
23 0.5 0.125 1.0 0.5 0.75 additive 
30 1.0 0.25 2.0 0.064 0.282 synergistic 
 
 40
Table 10: Antibiotic combination MICs and FIC index- checkerboard method (isolates 9 & 23 done in 
duplicate to assess reproducibility) 
Rif + tob 
Isolate MIC rif 
(µg/ml) 
MIC rif+tob MIC tob 
(µg/ml) 
MIC tob+rif FIC 
index 
interpretation 
1 4.0 0.25 4.0 2.0 0.563 additive 
9a 2.0 0.5 0.25 0.125 0.75 additive 
9b 2.0 1.0 0.25 0.125 1.0 additive 
14 0.5 0.25 2.0 0.5 0.75 additive 
16 1.0 1.0 4.0 0.5 1.125 indifferent 
17 2.0 2.0 16 4.0 1.25 indifferent 
23a 1.0 1.0 1.0 0.125 1.125 Indifferent 
23b 1.0 1.0 1.0 0.25 1.25 Indifferent 
25 0.5 0.064 1.0 0.064 0.192 synergistic 
30 1.0 1.0 2.0 0.125 1.063 indifferent 
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Table 11: Antibiotic combination MICs and FIC index - checkerboard method (isolate 16 done in duplicate 
to assess reproducibility) 
Rif + imi 
Isolate MIC rif 
(µg/ml) 
MIC rif+imi MIC imi 
(µg/ml) 
MIC imi+rif FIC 
index 
interpretation 
9 4.0 1.0 0.064 0.032 0.75 additive 
14 0.5 0.5 0.064 0.032 1.5 indifferent 
16a 1.0 0.5 0.125 0.064 1.012 indifferent 
16b 2.0 0.25 0.125 0.064 0.637 additive 
17 4.0 2.0 0.25 0.064 0.756 additive 
 
 
Table 12: Antibiotic combination MICs and FIC index - checkerboard method (isolate 16 done in duplicate 
to assess reproducibility) 
Imi + tob 
Isolate MIC imi 
(µg/ml) 
MIC imi+tob MIC tob 
(µg/ml) 
MIC tob+imi FIC 
index 
interpretation 
9 0.25 0.032 0.25 0.25 1.128 indifferent 
14 0.032 0.064 4.0 0.5 2.125 indifferent 
16a 0.064 0.016 4.0 2.0 0.75 additive 
16b 0.064 0.032 4.0 2.0 1.0 additive 
17 0.064 0.032 16 8.0 1.031 indifferent 
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Comparison of the results obtained with the E-test and checkerboard methods: 
 
Tables 13-18 give the results obtained for isolates tested with both combination testing methods for the 
respective antibiotic combinations. The median MIC values were used for the calculation of the FIC index in 
the combination testing methods. It is noted that for most antibiotic combinations an indifferent/additive 
result was obtained. However, for the col + rif combination, the checkerboard method showed synergism 
for 4 of 6 isolates, whereas the E-test method showed indifference and an additive result in one. For the col 
+ tob combination, synergism was shown in one isolate with the checkerboard method, whereas the E-test 
method showed an additive result. In another isolate tested with this combination, antagonism was found 
with the E-test method, but the checkerboard reaction showed indifference. For rif + tob, synergism was 
also shown with the checkerboard method in one isolate; however the E-test result was indifferent. 
 
Table 13: Comparison of E-test and checkerboard methods 
Col + rif 
Isolate number Interpretation – E-test Interpretation-
checkerboard 
1 indifferent indifferent 
3 indifferent synergistic 
6 Indifferent synergistic 
16 Indifferent indifferent 
23 additive synergistic 
30 indifferent synergistic 
 
Table 14: Comparison of E-test and checkerboard methods 
Col + imi 
Isolate number Interpretation – E-test Interpretation-
checkerboard 
9 indifferent 9a indifferent 
9b additive 
16 indifferent indifferent 
17 indifferent indifferent 
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Table 15: Comparison of E-test and checkerboard methods 
Col + tob 
Isolate number Interpretation – E-test Interpretation-
checkerboard 
9 indifferent additive 
14 indifferent indifferent 
16 antagonistic indifferent 
23 indifferent additive 
30 additive synergistic 
 
Table 16: Comparison of E-test and checkerboard methods 
Rif + tob 
Isolate number Interpretation – E-test Interpretation-
checkerboard 
1 indifferent additive 
9 indifferent additive 
14 Indifferent additive 
16 Indifferent indifferent 
17 Indifferent indifferent 
23 additive indifferent 
25 Indifferent synergistic 
30 indifferent indifferent 
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Table 17: Comparison of E-test and checkerboard methods 
Rif + imi 
Isolate number Interpretation – E-
test 
Interpretation-
checkerboard 
9 indifferent additive 
14 indifferent indifferent 
16 indifferent 16a indifferent 
16b additive 
17 indifferent additive 
 
Table 18: Comparison of E-test and checkerboard methods 
Imi + tob  
Isolate number Interpretation – E-test Interpretation-
checkerboard 
9 indifferent indifferent 
14 indifferent indifferent 
16 indifferent indifferent 
17 indifferent indifferent 
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VIII.  Discussion 
Acinetobacter baumannii is a serious growing problem worldwide due to its multidrug resistance. Few 
antibiotics may be active against this species. Presently there are no particularly promising antibiotics on 
the horizon for the near future (Timurkaynak F., 2006). This has resulted in the use of old drugs, like 
colistin, until new antibiotics can be developed (Li J., 2006). Colistin belongs to the polymyxin family. 
Information about the pharmacokinetic, pharmacodynamic and toxic profile of colistin is limited. This 
antibiotic was discovered over 50 years ago, thus it was never exposed to drug development processes 
needed for compliance with contemporary regulatory requirements (Li J., 2006). In line with the literature, it 
was established in this study that compared with rifampicin, imipenem and tobramycin; colistin had the best 
in vitro activity against all the tested A. baumannii isolates which showed 100% susceptibility to colistin.  
 
In the present study MIC determination by E-test was compared to the broth microdilution method. Overall 
good reproducibility was obtained with both methods. The agreement of MICs between the broth dilution 
and E-test methods was good with not more than 2 dilution differences in MIC values for most isolates. The 
E-test MICs matched the broth microdilution MICs or differed by 1 double dilution in 73% of tests. However, 
the categorical agreement between the methods for rifampicin was poor. Although MICs did not differ with 
more than two dilutions in most cases, many major errors occurred because the MICs clustered around the 
breakpoints. 
 The results of the disk diffusion for imipenem and tobramycin as tested in the routine microbiology 
laboratory were also presented. There was generally good correlation between the broth microdilution, E-
test and disk diffusion methods for imipenem. Tobramycin MICs showed good correlation between E-test 
and broth dilution methods, but some errors were noted with the disk diffusion method. Swensen et al 
(Swensen J.M., 2004) compared the broth dilution and the disk diffusion methods and found that 
categorical agreement for tobramycin and imipenem were comparable for these two methods.  
 
Published information regarding the treatment of multidrug resistant A. baumannii is limited (Manikal V.M., 
2000). Because of the nephrotoxicity and neurotoxicity which are reported to be associated with colistin, the 
combination of colistin with other antibiotics was tested. The antibiotic combinations might allow the use of 
lower concentrations of the antibiotics, thus minimizing toxicity. Colistin in combination is suggested to 
cause rapid permeabilization of the outer cell membrane, thus allowing increased penetration by and 
activity of the other antibiotic in combination (Yoon J., 2004). In our study, synergy was demonstrated 
between colistin and rifampicin for four of the six tested isolates by the checkerboard method. All these 
isolates were resistant to rifampicin individually. The E-test method showed indifferent results for all these 
isolates, except one, which showed additive results.  
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There are few studies that have reported on the activity of antibiotic combination against A. baumannii. 
Most have produced variable results, probably due to differences in the strains selected and/or the methods 
used to evaluate synergy (Haddad F.A., 2005). Rifampicin has been shown to be bactericidal in vitro 
against A. baumannii (Thornberry C., 1983). The combination of colistin and rifampicin acted synergistically 
against A. baumannii in a number of studies (Giamarellos-Bourboulis E.J., 2001; Hogg G.M., 1998, 
Timurkaynak F., 2006; Tripodi M., 2007). Hogg et al used the checkerboard method to assess in vitro 
activity of colistin + rifampicin against 13 strains of A. baumannii (Hogg G.M., 1998). The combination of 
colistin and rifampicin was synergistic against 11 isolates (FICs, 0.07 – 0.063) and indifferent against two 
isolates. No antagonism was observed in that study. Time-kill method was used by Giamarellos-Bourboulis 
et al (Giamarellos-Bourboulis E.J., 2001) to investigate the interaction of colistin and rifampicin on 39 
multidrug-resistant (MDR) A. baumannii isolates. Synergy was observed in six isolates (15.4%) at 6h of 
growth and in 20 isolates (51.3%) at 24h of growth. No synergy was found at 2 and 4h of growth 
(Giamarellos-Bourboulis E.J., 2001). Timurkaynak et al assessed the in vitro activity of colistin, 
azithromycin, doxycycline and rifampicin against five MDR strains of A. baumannii and five MDR strains of 
Pseudomonas aeruginosa. They also used the checkerboard method to determine whether the 
combinations of colistin with the abovementioned antibiotics act synergistically against these strains. The 
combination of colistin and rifampicin was synergistic against four A. baumannii and two P. aeruginosa 
strains (Timurkaynak F., 2006). Tripodi et al used time kill studies to evaluate nine MDR A. baumannii 
isolates using colistin, rifampicin, imipenem and sulbactam/ampicillin (Tripodi M., 2007). Synergy was 
observed with combinations of rifampicin + imipenem or sulbactam/ampicillin for all isolates and with 
colistin + rifampicin for isolates showing higher (4µg/ml) minimum inhibitory concentrations for rifampicin  
Co-administration of rifampicin with colistin enhances colistin activity (Pantopoulou A., 2007). The best in 
vitro results were observed when rifampicin was combined with colistin. Even though colistin is associated 
with nephrotoxicity, in patients without underlying renal disease, 7–11 days of colistin/rifampicin 
combination would be safe without serious adverse events (Song J.Y., 2008). 
 
The combination of colistin and imipenem showed indifferent results by both the E-test and checkerboard 
methods, except for one isolate which was additive by checkerboard method. All the tested isolates were 
individually susceptible to both antibiotics. The results in our study differed to those of Manikal et al 
(Manikal V.M., 2000) and Haddad et al (Haddad F.A., 2005) which demonstrated additive and synergistic 
results by E-test and checkerboard methods, respectively, rather than indifferent results. Souli et al (Souli 
M., 2009) also concluded in their study that colistin and imipenem combination improved bactericidal 
activity against Klebsiella pneumoniae isolates susceptible either to both agents or to colistin. In this study 
both the checkerboard and E-test methods gave indifferent results, no synergy or antagonism was found 
for the colistin/imipenem combination. This is probably due to the low number of isolates tested that no 
synergy was observed. 
 
The combinations of rifampicin and imipenem showed indifferent results by E-test, but additive results by 
checkerboard. The selected isolates tested with both combination methods were all susceptible to 
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imipenem individually. Saballs et al (Saballs M., 2006) treated 10 patients with different clinical 
presentations, who were infected with carbapenem resistant A. baumannii. Seven patients were clinically 
cured by the rifampicin/imipenem combination. In that study in vitro development of high level resistance 
(MIC = 256 mg/l) to rifampicin was observed in seven (70%) of the treated patients during treatment. The 
authors concluded that the rifampicin/imipenem combination should not be used against carbapenem 
resistant A. baumannii isolates (Saballs M., 2006). In a mouse pneumonia mouse model study by Montero 
et al, it was shown that a combination of rifampicin with imipenem, tobramycin or colistin may be useful 
(Montero) against carbapenem resistant A baumannii isolates. The combination of imipenem and 
tobramycin was the most active therapy against pneumonia caused by moderately carbapenem-resistant 
(imipenem MIC 8mg/l) strains. Our in vitro study showed indifferent results for this combination by both E-
test and checkerboard method, except for one isolate which was additive by the latter method. 
 
When results obtained with the E-test and checkerboard methods were compared, there was generally 
good agreement between the methods, except for the combinations of colistin/rifampicin and 
rifampicin/tobramycin. The checkerboard method showed more synergy results than the E-test method 
which showed more indifferent results for the colistin/rifampicin combination. For the rifampicin/tobramycin 
combination, the checkerboard method showed additive results compared to indifferent E-test results. 
Whereas more synergism or additivity was observed using the checkerboard methods in our study (Tables 
13-18), the E-test method revealed indifference more frequently. There was no antagonism detected by the 
checkerboard method and one was detected by E-test method. In another study by White et al, that 
compared E-test, checkerboard, and time kill methods for detecting synergy, concordance between the E 
test and the checkerboard or time-kill curves method was present in 75% of cases. When the same 
methods were compared against A. baumannii, synergy was not detected by the E-test method (Bonapace 
C.R., 2000). This finding is similar to our present study, as the E-test method failed to detect synergy. The 
difference between our study and the one by Bonapace et al is that E-test strips were crossed at a 900 
angle so that the scales met at the MIC of each drug alone, and the fractional inhibitory concentration index 
was calculated on the basis of the resultant zone of inhibition. The study by Manno et al (Manno G., 2003), 
which used the same E-test overlay method as ours, against Burkholderia cepacia complex, agreement 
between the E test and checkerboard was observed in 18 of 20 instances. 
 
Data regarding the best combinations for synergy, as mentioned above, is mostly derived from in vitro and 
in vivo animal studies (Karageorgopoulos D.E., 2008). The good results obtained from these studies do not 
necessarily correlate with clinical findings (Karageorgopoulos D.E., 2008). It is also worthwhile to note that 
when interpreting the results of combination studies, one must take into account the important fact that 
what is called synergism may not be clinically relevant because such an interaction may occur in vitro only 
with antibiotic concentrations that are higher than those that can be achieved in patients (Moellering R.C. 
1978). Clinical trials are too few to recommend the use of specific combinations for the treatment of 
multidrug-resistant A. baumannii (Towner 2009, Karageorgopoulos D.E., 2008). 
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From this study there was reasonable correlation between the checkerboard and E-test methods but 
synergy was detected for the rifampicin/colistin combination by checkerboard method, and not by E-test. 
The checkerboard method is indeed laborious, time consuming, expensive, and not suitable for the routine 
microbiology laboratory. More studies need to be performed to assess correlation between the E-test and 
checkerboard methods with a higher number of isolates. This study was limited by low numbers of selected 
isolates. The checkerboard method is indeed not an easy method to perform and expertise is needed to 
perform this method. Genotypic analysis using pulsed-field gel electrophoresis (PFGE) may be considered 
in future studies to determine relatedness of the isolates which will facilitate the selection of different strains 
for synergy testing. Furthermore, clinical studies are needed to establish whether in vitro synergy testing is 
useful in the clinical setting and whether the results of synergy testing will have any bearing on the clinical 
outcome of patients infected with multidrug resistant A. baumannii.  
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IX. Conclusions 
The combination of colistin and rifampicin was synergistic against most A. baumannii isolates which were 
selected for this study. Synergy was detected by the checkerboard method; however the E-test method 
failed to detected synergism. Most combinations were indifferent and some additive by E-test method. 
There was good correlation between E-test and broth microdilution methods for the determination of 
colistin, imipenem, tobramycin and rifampicin MICs against A. baumannii. More studies to compare the 
checkerboard and E-test methods are needed as the latter method is much easier to perform and may be 
suitable for routine laboratory testing. In addition, clinical studies to investigate the usefulness of in vitro 
synergy testing in the clinical setting are recommended. 
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APPENDIX A 
 
Table 1: MIC determined by E-test method – colistin (a, b & c = MICs done in triplicate) 
Isolate number E-test MIC’s 
µg/ml  
interpretation 
a b c Median 
1 0.5 0.5 0.5 0.5 S 
3 0.5 1.0 1.0 1.0 S 
6 0.5 1.0 1.0 1.0 S 
9 0.5 0.5 0.5 0.5 S 
14 0.5 1.0 0.5 0.5 S 
16 0.5 0.5 0.5 0.5 S 
17 0.5 0.5 0.5 0.5 S 
23 1.0 1.0 1.0 1.0 S 
25 0.5 1.0 1.0 1.0 S 
30 1.0 1.0 1.0 1.0 S 
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Table 2: MIC by broth microdilution – colistin (a, b & c = MICs done in triplicate) 
Isolate number Broth microdilution MIC’s 
µg/ml  
interpretation 
a b c Median 
1 1.0 2.0 2.0 2.0 S 
3 2.0 2.0 2.0 2.0 S 
6 2.0 2.0 2.0 2.0 S 
9 1.0 2.0 1.0 1.0 S 
14 2.0 2.0 1.0 2.0 S 
16 1.0 1.0 2.0 1.0 S 
17 2.0 1.0 2.0 2.0 S 
23 1.0 1.0 1.0 1.0 S 
25 1.0 1.0 1.0 1.0 S 
30 0.25 1.0 0.25 0.25 S 
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Table 3: MIC by E-test method – rifampicin 
Isolate number E-test MIC’s 
µg/ml  
interpretation 
a b c Median 
1 4.0 4.0 8.0 4.0 R 
3 8.0 4.0 4.0 4.0 R 
6 8.0 8.0 8.0 8.0 R 
9 8.0 4.0 8.0 8.0 R 
14 2.0 4.0 4.0 4.0 R 
16 4.0 4.0 4.0 4.0 R 
17 4.0 4.0 4.0 4.0 R 
23 4.0 4.0 4.0 4.0 R 
25 4.0 4.0 4.0 4.0 R 
30 4.0 4.0 4.0 4.0 R 
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Table 4: MIC by broth microdilution – rifampicin 
Isolate number Broth microdilution MIC’s 
µg/ml  
interpretation 
a b c Median 
1 2.0 2.0 4.0 2.0 S 
3 4.0 8.0 8.0 8.0 R 
6 2.0 2.0 8.0 2.0 S 
9 4.0 4.0 8.0 4.0 R 
14 2.0 2.0 8.0 2.0 S 
16 2.0 2.0 4.0 2.0 S 
17 4.0 4.0 4.0 4.0 R 
23 1.0 4.0 1.0 1.0 S 
25 1.0 2.0 0.5 1.0 S 
30 0.5 0.5 0.5 0.5 S 
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Table 5: MIC by E-test method – imipenem 
Isolate number E-test MIC’s 
µg/ml  
interpretation 
a b c Median 
1 8.0 8.0 8.0 8.0 I 
3 16.0 8.0 8.0 8.0 I 
6 16.0 16.0 16.0 16.0 R 
9 0.25 0.25 0.25 0.25 S 
14 0.25 0.25 0.25 0.25 S 
16 0.25 0.25 0.25 0.25 S 
17 0.25 0.25 0.25 0.25 S 
23 32. 32 32 32 R 
25 >32 >32 >32 >32 R 
30 32 >32 >32 >32 R 
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Table 6: MIC by broth microdilution – imipenem 
Isolate number Broth microdilution MIC’s 
µg/ml  
interpretation 
a b c Median 
1 32 32 32 32 R 
3 32 32 32 32 R 
6 32 32 32 32 R 
9 0.125 0.125 4.0 0.125 S 
14 0.125 0.25 16 0.25 S 
16 0.125 0.125 0.25 0.125 S 
17 0.125 0.125 0.25 0.125 S 
23 >32 >32 >32 >32 R 
25 >32 >32 >32 >32 R 
30 >32 >32 >32 >32 R 
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Table 7: MIC by E-test method – tobramycin 
Isolate number E-test MIC’s 
µg/ml  
interpretation 
a b c Median 
1 2.0 4.0 4.0 4.0 S 
3 256 128 128 128 R 
6 2.0 2.0 2.0 2.0 S 
9 2.0 1.0 1.0 1.0 S 
14 8.0 8.0 8.0 8.0 I 
16 4.0 4.0 8.0 4.0 S 
17 16 16 16 16 R 
23 2.0 2.0 2.0 2.0 S 
25 1.0 1.0 1.0 1.0 S 
30 1.0 2.0 2.0 2.0 S 
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Table 8: MIC by broth microdilution – tobramycin 
Isolate number Broth microdilution MIC’s 
µg/ml  
interpretation 
a b c Median 
1 8.0 16 64 16 R 
3 >64 >64 >64 >64 R 
6 2.0 2.0 8.0 2.0 S 
9 2.0 0.5 1.0 1.0 S 
14 4.0 4.0 32 4.0 S 
16 2.0 2.0 16 2.0 S 
17 16 32 32 32 R 
23 1.0 0.5 2.0 1.0 S 
25 0.5 0.5 1.0 0.5 S 
30 0.5 0.5 1.0 0.5 S 
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Table 9 MICs of colistin, rifampicin, imipenem, and tobramycin by E-test and broth microdilution methods 
together with disk diffusion results for imipenem and tobramycin 
Isolate 
no. 
MIC (median values)µg/ml 
Col rif Imi tob 
E-test Broth 
microdi
-lution 
E-test Broth 
microdi
-lution 
E-test Broth 
microdi- 
lution 
Disk 
diffusion 
E-test Broth 
microdi
-lution 
Disk 
diffusion 
1 0.5(S) 2.0(S) 4.0(R) 2.0(S) 8.0(I) 32(R) R 4.0(S) 16(R) S 
3 1.0(S) 2.0(S) 4.0(R) 8.0(R) 8.0(I) 32(R) R 128(R) >64(R) R 
6 1.0(S) 2.0(S) 8.0(R) 2.0(S) 16(R) 32(R) R 2.0(S) 2.0(S) R 
9 0.5(S) 1.0(S) 8.0(R) 4.0(R) 0.25(S) 0.125(S) S 1.0(S) 1.0(S) S 
14 0.5(S) 2.0(S) 4.0(R) 2.0(S) 0.25(S) 0.25(S) S 8.0(I) 4.0(S) R 
16 0.5(S) 1.0(S) 4.0(R) 2.0(S) 0.25(S) 0.125(S) S 4.0(S) 2.0(S) R 
17 0.5(S) 2.0(S) 4.0(R) 4.0(R) 0.25(S) 0.125(S) S 16(R) 32(R) R 
23 1.0(S) 1.0(S) 4.0(R) 1.0(S) 32(R) >32(R) R 2.0(S) 1.0(S) S 
25 1.0(S) 1.0(S) 4.0(R) 1.0(S) >32(R) >32(R) R 1.0(S) 0.5(S) S 
30 1.0(S) 0.25(S) 4.0(R) 0.5(S) >32(R) >32(R) S 2.0(S) 0.5(S) S 
S, susceptible, I, intermediate, R, resistant 
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APPENDIX B 
 
Table 1: Antibiotic combination MIC- Etest method 
Isolate Antibiotic 
combination 
MIC’s 
(µg/ml) – a 
b c median 
1 Col + Rif 0.5 0.5 0.5 0.5 
 Rif  + col 0.016 0.032 0.064 0.032 
 Col + imi 1.0 1.0 0.5 1.0 
 Imi + col 0.125 0.064 0.125 0.125 
 Col + tob 1.0 0.5 1.0 1.0 
 Tob + col 0.5 1.0 1.0 1.0 
 Rif + tob 0.5 0.5 0.25 0.5 
 Tob + rif 2.0 4.0 4.0 4.0 
 Rif + imi 4.0 4.0 2.0 4.0 
 Imi + rif 4.0 4.0 4.0 4.0 
 Imi + tob 0.25 0.5 0.5 0.5 
 Tob + imi 4.0 4.0 2.0 4.0 
 
col, colistin; rif, rifampicin; imi, imipenem; tob, tobramycin 
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Table 2: Antibiotic combination MIC- Etest method 
Isolate Antibiotic 
combination 
MIC–
(µg/ml)-a 
b c median 
3 Col + Rif 1.0 1.0 1.0 1.0 
 Rif  + col 0.125 0.25 0.064 0.125 
 Col + imi 1.0 1.0 1.0 1.0 
 Imi + col 0.125 0.125 0.125 0.125 
 Col + tob 1.0 1.0 1.0 1.0 
 Tob + col 2.0 1.0 1.0 1.0 
 Rif + tob 4.0 4.0 4.0 4.0 
 Tob + rif 32 32 64 32 
 Rif + imi 4.0 4.0 4.0 4.0 
 Imi + rif 4.0 4.0 4.0 4.0 
 Imi + tob 8.0 4.0 16 8.0 
 Tob + imi 128 32 64 64 
 
col, colistin; rif, rifampicin; imi, imipenem; tob, tobramycin 
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Table 3: Antibiotic combination MIC- Etest method 
Isolate Antibiotic 
combination 
MIC – 
(µg/ml)-a 
b c median 
6 Col + Rif 2.0 1.0 1.0 1.0 
 Rif  + col 0.064 0.125 0.125 0.125 
 Col + imi 2.0 1.0 1.0 1.0 
 Imi + col 0.125 0.125 0.125 0.125 
 Col + tob 2.0 1.0 2.0 2.0 
 Tob + col 1.0 1.0 2.0 1.0 
 Rif + tob 0.5 0.5 0.25 0.5 
 Tob + rif 4.0 4.0 4.0 4.0 
 Rif + imi 8.0 8.0 8.0 8.0 
 Imi + rif 8.0 4.0 4.0 4.0 
 Imi + tob 0.25 0.25 0.25 0.25 
 Tob + imi 4.0 2.0 2.0 2.0 
 
col, colistin; rif, rifampicin; imi, imipenem; tob, tobramycin 
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Table 4: Antibiotic combination MIC- Etest method 
Isolate Antibiotic 
combination 
MIC – 
(µg/ml)-a 
b c median 
9 Col + Rif 1.0 1.0 0.5 1.0 
 Rif  + col 0.064 0.064 0.064 0.064 
 Col + imi 1.0 1.0 1.0 1.0 
 Imi + col 0.25 0.125 0.064 0.125 
 Col + tob 1.0 0.5 0.5 0.5 
 Tob + col 0.5 1.0 1.0 1.0 
 Rif + tob 0.125 0.25 0.125 0.125 
 Tob + rif 2.0 1.0 1.0 1.0 
 Rif + imi 0.125 0.5 0.25 0.25 
 Imi + rif 0.25 0.25 0.25 0.25 
 Imi + tob 0.125 0.125 0.125 0.125 
 Tob + imi 1.0 1.0 0.5 1.0 
 
col, colistin; rif, rifampicin; imi, imipenem; tob, tobramycin 
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Table 5: Antibiotic combination MIC- Etest method 
Isolate Antibiotic 
combination 
MIC – 
( µg/ml)- a 
b c median 
14 Col + Rif 1.0 1.0 1.0 1.0 
 Rif  + col 0.064 0.064 0.25 0.064 
 Col + imi 2.0 1.0 1.0 1.0 
 Imi + col 0.064 0.125 0.125 0.125 
 Col + tob 2.0 0.5 1.0 1.0 
 Tob + col 1.0 1.0 1.0 1.0 
 Rif + tob 2.0 2.0 0.5 2.0 
 Tob + rif 8.0 8.0 8.0 8.0 
 Rif + imi 0.125 0.25 0.25 0.25 
 Imi + rif 0.25 0.25 0.25 0.25 
 Imi + tob 0.25 0.25 0.25 0.25 
 Tob + imi 4.0 4.0 2.0 4.0 
 
col, colistin; rif, rifampicin; imi, imipenem; tob, tobramycin 
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Table 6: Antibiotic combination MIC- Etest method 
Isolate Antibiotic 
combination 
MIC – 
( µg/ml) a 
b c median 
16 Col + Rif 0.064 0.5 0.5 0.5 
 Rif  + col 0.064 0.064 0.064 0.064 
 Col + imi 1.0 1.0 1.0 1.0 
 Imi + col 0.25 0.25 0.25 0.25 
 Col + tob 2.0 2.0 1.0 2.0 
 Tob + col 4.0 4.0 0.5 4.0 
 Rif + tob 0.5 0.5 0.25 0.5 
 Tob + rif 4.0 4.0 8.0 4.0 
 Rif + imi 0.5 0.5 0.25 0.5 
 Imi + rif 0.25 0.25 0.25 0.25 
 Imi + tob 0.25 0.25 0.125 0.25 
 Tob + imi 2.0 2.0 4.0 2.0 
 
col, colistin; rif, rifampicin; imi, imipenem; tob, tobramycin 
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Table 7: Antibiotic combination MIC- Etest method 
Isolate Antibiotic 
combination 
MIC – 
( µg/ml)- a 
b c median 
17 Col + Rif 0.5 0.5 1.0 0.5 
 Rif  + col 0.064 0.125 0.064 0.064 
 Col + imi 1.0 1.0 1.0 1.0 
 Imi + col 0.25 0.25 0.25 0.25 
 Col + tob 0.5 0.5 0.5 0.5 
 Tob + col 1.0 1.0 0.5 1.0 
 Rif + tob 2.0 2.0 2.0 2.0 
 Tob + rif 16 16 16 16 
 Rif + imi 0.5 0.5 0.5 0.5 
 Imi + rif 0.25 0.25 0.25 0.25 
 Imi + tob 0.25 0.25 0.25 0.25 
 Tob + imi 4.0 4.0 4.0 4.0 
 
col, colistin; rif, rifampicin; imi, imipenem; tob, tobramycin 
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Table 8: Antibiotic combination MIC- Etest method 
Isolate Antibiotic 
combination 
MIC – 
( µg/ml)- a 
b c median 
23 Col + Rif 0.5 0.5 0.5 0.5 
 Rif  + col 0.064 0.064 0.064 0.064 
 Col + imi 1.0 0.5 0.5 0.5 
 Imi + col 0.125 0.25 0.25 0.25 
 Col + tob 1.0 1.0 1.0 1.0 
 Tob + col 0.5 0.5 0.5 0.5 
 Rif + tob 0.25 0.5 0.5 0.5 
 Tob + rif 1.0 1.0 1.0 1.0 
 Rif + imi 4.0 8.0 8.0 8.0 
 Imi + rif 4.0 4.0 4.0 4.0 
 Imi + tob 0.5 0.25 0.25 0.25 
 Tob + imi 1.0 1.0 1.0 1.0 
 
col, colistin; rif, rifampicin; imi, imipenem; tob, tobramycin 
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Table 9: Antibiotic combination MIC- Etest method 
Isolate Antibiotic 
combination 
MIC – 
( µg/ml)- a 
b c median 
25 Col + Rif 0.5 0.5 0.5 0.5 
 Rif  + col 0.064 0.064 0.064 0.064 
 Col + imi 1.0 1.0 1.0 1.0 
 Imi + col 0.125 0.125 0.0125 0.125 
 Col + tob 0.5 0.5 0.5 0.5 
 Tob + col 1.0 1.0 1.0 1.0 
 Rif + tob 0.125 0.125 0.064 0.125 
 Tob + rif 1.0 1.0 1.0 1.0 
 Rif + imi 4.0 4.0 4.0 4.0 
 Imi + rif 8.0 8.0 4.0 8.0 
 Imi + tob 0.125 0.125 0.125 0.125 
 Tob + imi 1.0 1.0 0.5 1.0 
 
col, colistin; rif, rifampicin; imi, imipenem; tob, tobramycin 
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Table 10: Antibiotic combination MIC- Etest method 
Isolate Antibiotic 
combination 
MIC – 
(µg/ml)- a 
b c median 
30 Col + Rif 1.0 1.0 1.0 1.0 
 Rif  + col 0.125 0.125 0.125 0.125 
 Col + imi 1.0 1.0 1.0 1.0 
 Imi + col 0.125 0.125 0.125 0.125 
 Col + tob 0.5 0.5 0.5 0.5 
 Tob + col 1.0 1.0 1.0 1.0 
 Rif + tob 0.125 0.125 0.125 0.125 
 Tob + rif 2.0 2.0 2.0 2.0 
 Rif + imi 4.0 4.0 4.0 4.0 
 Imi + rif 4.0 4.0 4.0 4.0 
 Imi + tob 0.064 1.064 0.064 0.064 
 Tob + imi 2.0 2.0 2.0 2.0 
 
col, colistin; rif, rifampicin; imi, imipenem; tob, tobramycin 
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APPENDIX C 
 
 
Example of a broth microdilution checkerboard panel (Reproduced from Schwalbe et al., 2007) 
 
 
 
 
 
 
 
 
 
 
 
 
